795 users online (112 members and 683 guests)  


Websleuths News


Page 1 of 57 1 2 3 11 51 ... LastLast
Results 1 to 15 of 841
  1. #1
    Join Date
    Oct 2008
    Posts
    9,462

    Ebola outbreak - general thread #9

    Mod note: Statements/announcements or other news from political figures about ebola (President, mayor, governor, etc.) belong in the following thread:

    http://www.websleuths.com/forums/sho...gious-Diseases

    The Ebola thread in the 'Up to the Minute' area concerns discussion about the disease itself and the efforts to contain it and control it's spread.
    Last edited by Harmony 2; 10-30-2014 at 09:33 PM.

  2. #2
    Join Date
    Oct 2008
    Posts
    9,462

    Ebola outbreak - general thread #9

    Continue discussion here...

    1) Blogs must be approved before posting.

    2) Please read your post before hitting reply. If your post is personal to someone else, don't post it.

    3) Posts about the political aspects need to be taken to the designated area on the forum. This is the link for political posts about ebola: http://www.websleuths.com/forums/sho...gious-Diseases

    4) Post responsibly by linking to information.

    5) Keep information relevant to the disease and steer away from bashing victims, conspiracy theories and race.

    The guidelines above have been posted several times; therefore, any infractions will result in time-outs.

  3. #3
    Quote Originally Posted by Inthedetails View Post
    So this 82% would put all health-care workers who work with ebola patients in a hospital in quarantine? Was that the question?
    Yes, either way they want them quarantined.

  4. #4
    SteveS is offline Attention: All my comments are IMO JMO MOO AFAIK etc
    Join Date
    Feb 2014
    Location
    Texas
    Posts
    3,095
    Quote Originally Posted by JudyBolton View Post
    So if I quoted a woman who said, "The New York City Health Department finally sent Dr. _____to talk to ___. He stated "by that time she was convinced that the law was only persecuting her when she had done nothing wrong." Who would you think I was talking about? a certain nurse with the intials K.H.?

    You would be wrong - those were the feelings of Mary Mallon(aka: Typhoid Mary) who infected 53 people with typhoid fever and refused to be quarantined or even examined by a doctor - she hid in the bathroom when they tried to interview her....

    "there was no policy providing guidelines for handling the situation. Some difficulties surrounding her case stemmed from Mallon's vehement denial of her possible role, as she refused to acknowledge any connection between her working as a cook and the typhoid cases."
    So now we are equating a woman who has NEVER exhibited a symptom, who cannot infect anyone, and who has NEVER infected anyone ever, with a woman who had infected many ...and the suggestion is that we should treat both the same?

    <modsnip> The ladies are polar opposites. Kaci has no symptoms, has been tested when asked (twice), and has been monitored (and is self-monitoring). There's been no suggestion that she wouldn't run straight to the hospital if she showed symptoms.
    Last edited by Harmony 2; 10-31-2014 at 02:25 PM. Reason: negative characterization

  5. #5
    Join Date
    Jun 2012
    Location
    America
    Posts
    22,125

    Just tiny example of what we DO know! tiny tiny !

    Post last thread referring to Ebola as being uncharted territory

    Its uncharted for CNN. Not for scholarly, peer reviewed, published academic journals. If I seriously tried to get a real list I would crash WS and miss ya guys!


    Myron M. Levine, Milagritos Tapia, Adrian V. Hill, et al.
    14 September 2014, Advance AccessDNA Vaccines Encoding Ebolavirus and Marburgvirus Wild Type Glycoproteins are Safe and Immunogenic in a Phase I Clinical TrialUzma N. Sarwar, Pamela Costner, Mary E. Enama, et al.14 September 2014, Advance AccessA Practical Treatment for Patients with Ebola Virus DiseaseDavi S. Fedson25 August 2014; Advance AccessReply to FedsonAnita K. McElroy and Christina F Spiropoulou
    25 August 2014; Advance AccessEbola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical OutcomeAnita K. McElroy, Bobbie R. Erickson, Timothy D. Flietstra, et al.15 August 2014; 210 (4): 558 - 566Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic FeverLauren M. Smith, Lisa E. Hensley, Thomas W. Geisbert, et al.15 July 2013; 208 (2): 310 - 318A Syrian Golden Hamster Model Recapitulating Ebola Hemorrhagic FeverHideki Ebihara, Marko Zivcec, Donald Gardner, et al15 January 2013; 207 (2): 306 - 318Reston ebolavirus in Humans and Animals in the Philippines: A ReviewMary Elizabeth G. Miranda and Noel Lee J. Miranda1 November 2011; 204: S757 - S760Management of Accidental Exposure to Ebola Virus in the Biosafety Level 4 Laboratory, Hamburg, GermanyStephan Günther, Heinz Feldmann, Thomas W. Geisbert, et al.1 November 2011; 204: S785 - S790Ebola Reston Virus Infection of Pigs: Clinical Significance and Transmission PotentialGlenn A. Marsh, Jessica Haining, Rachel Robinson, et al.1 November 2011; 204: S804 - S809Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever Mark G. Kortepeter, Daniel G. Bausch, and Mike Bray1 November 2011; 204: S810 - S816Characterization of Filovirus Protein–Protein Interactions in Mammalian Cells Using Bimolecular ComplementationYuliang Liu, Sasha Stone, and Ronald N. Harty1 November 2011; 204: S817 - S824Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat CellsAnnika Kühl, Markus Hoffmann, Marcel A. Müller, et al.1 November 2011; 204: S840 - S849DRBP76 Associates With Ebola Virus VP35 and Suppresses Viral Polymerase FunctionReed S. Shabman, Daisy W. Leung, Joshua Johnson, et al.1 November 2011; 204: S911 - S918Real-time Monitoring of Cardiovascular Function in Rhesus Macaques Infected With Zaire ebolavirusMark G. Kortepeter, James V. Lawler, Anna Honko et al.1 November 2011; 204: S1000 - S1010The Importance of the NP: VP35 Ratio in Ebola Virus Nucleocapsid FormationTakeshi Noda, Larissa Kolesnikova, Stephan Becker, et al.1 November 2011; 204: S878 - S883[IMG]http://www.websleuths.com/forums/image/png;******,iVBORw0KGgoAAAANSUhEUgAAAIUAAACvCAMAAAD kM 1eAAADAFBMVEU8PTw0NDQqKioqGlc2HVsiFU45HmI1IV47I2Qr I2EfGVBCHV5OHmdFMU5HJWlMKXRONHRUKG1YK3hYNHhTNW9lJV dlJW1mK3hmNXt4Knl1NX51K2FDQ0NMTExIR0hTU1NcXFxWWVdW SFJdYF1fYmBhU15pVWtkZGRsbGxrY2pxY210dHR8fHx2eXd5bH ZbLINbNIRmLIRpN4ZsP5J2LYh0O4x8PIt1N4Z5PZJqRYdtRZN4 RYt6R5R5VZVuUoh gX6YAAybABSeARygAx hBSKiCiWkDimmEy2pFS2rGC6nFjGnGDKoGTOqHzioFzKsJDytK D LL3euK0KsLE pJ0atLlCwLkawMEeyNEu0OU61PVKsN1SgNnOVQHuCdH63QVa5R Vq6Sl64Q1epSH68TmGzTH 9UmW/Vmm/WWnBXG3CXnDEY3TGanvIbn7FZ3jIcH GLYWFOYqGPZGXN4yYPJGXLIesOo2oNYqsPpGkPpGyPIy0OYizP pGsLoaDQ42IR4yERJOES5SLRJOMS5SIS5mNVJyHVJiVRY2US5W UTZmcTJWZR5aTVJuTWp2cVJucW56YU5WJUY6MWaGVXaKcXaGYV qCLa5OcY6SZaaeUcaiqSIikQ5OiTZmsQ5OsSpasTZikSpapVYe kVJulWZ6sVJusWp6jW5K0QY6zToC5Qo60RZK0SpazTpi6SpW5S ZazUYGzVJu0XJ66VJu5XJ6jXaGsXqGpV6C0XqC5XqCzVaCnY5a 3YZ kZKSsY6Otaaasbaqlaqiscq2mda2se7K1Y6K1aqa0bam5ZKO7a qa8bai2Zqi0cqy8cqq5ea 2e7KzbrHAVJvCSZbKc4LNfIrMeIbJb4DBaqfCcquEhISLi4uPg YuTk5OampqYiZO3hretibmmpqa7msLPgY7RhZLTi5fVkp3ZmqX Zm6XCjrvco6zfqrPep7Dgrrbhr7jis7vkuL/KmMLEp8jlvMPpxcvpxcvszNLu09fx2t7w19vy3eH36uz15uj57 vD68vP//v789/goETh3AAAv2klEQVR4nO18e1wUd5av2cwj89m7EHE2Eq JybgzMANspCOYCBmU7e5yqrvTseMM0LNXIEPaTiBMfEQSnPhAf ICIjpqFHUXYojskPJIuGuyORfHQqq5qQO MQAOL18wiyoibyQx8xEFie8/5VaP4GGHv/HH3jyntJ0X/vnXO93zPOb/fr5mj/ 9wzPn/DYAcf0Vx5/grijvHX1HcOf6K4s7xVxR3jtmj0AUeDf/lMQw6OO76qLtf3oXinp/cc1CUlsabVnvX2zRFUzOAoDW0ftqwOviYe0 ZQkGv0sF/ci78jp6G4y7AtNlsNiWZU9f0XIUT7rxtNJtSHg5CZ7rSowlcIn wkbRwce 1eGFMojCajyWQgQyfROtpkMhkNhmkwtCOX141fsYxmpU0aAk7B e3rNpZuZged3fDX9lVGv/eKy2qhTnsNxNdlinnYd01FQqemp5qwMq9X6hjXTajWbsq2vWc1 3INOGt7SJ17pXJFlM1/VqLZiD1mpwKI35Bk3rtegncBf6i9bSahqea/DnlEZrVFrCaItRraoLGMrtT GY/o6KSkV15JTk1OSTXDv1Rjsjk5KcU0HTJ8wLVujYEy/8ncZaX01JoeKzJEC7ahqfTsdRRtthqM69Iok8X0Voopw9STvUq vfaXHQquHAYVOrzVZs0xa/eVrFtN9DJzyCEXpgGdwaLUUhaxYRVP3nAwo1AZt8o2ec19lqs1 Da0YuaQx6bfqkUXNp0DhyVW39ykSPjKkzvro0ZrXe6sm60ZXYM 5QxmbFy HIiDGD 0rzuupkaHn8ICpPRaKIwgpARD44WgoIyT hXDF9ZOTJsvjyq1RvAFnTqBK0x3kyjrycnZo1qtH yJlKmiTUrBr9MzDYlXstagbYwaEa7ExOHx1ZmjSbe/9EBFDRQ4k3LG9Y3jKnp1ox7yXMbBXrkOjh6WD2eaU6B0wDFDW3 PdfDQ9R56IkXdM6bRj6fTtGnCpL74ezWVmT2eDbZQg88nM7Xar MnEc2Pa z86gEJnTElNTUtNTTeak82mB6IwqMd6Eg1UyrhefWl45fW3Vqj xXfAIte6mXktNZOgnTSt PppIX0vT0qbrpsTBkRWjF1eMZoItEg067fhQorp7bOXPv/zzttBTgUOP5HigKfSmyWG9gbLcSNaOjCZm YfOAUn12owJPTU6TL01QtHXh9OuXF9jmsym6LQbqerhscSxEfP 1YXrkCwqMtm7CbBy1JA6NP8DhgRjRmYxwZ3yF0hmMJsMDeWGwn utJp3XW7jRTT49JY7nag28mdo1ARPb0vInRfiUztceU1p1tpK3 d6aa3etaYhi2WrOSenmQao6kry6w1ZZ9Lv/8qp3hhedNiQWpYjRnW 0RFObRqNX6YBlUBJEKtAbCrzMPoPw2lhReUWktpaJAIHegEpcM z1aAkoBzkAymIPr1Oo3mAqW/HSEpaWuprqWlm/Z/jhX6aZN558lMDfqhx6h3dPafDOyC1dyVA4wM eQqFDtMSaAamkAcH6r2fhulPq3kA4e/8 M69/r7nD0Qx40FrtDjmdDPptOk9f8ZuoOBTJz08Vf/XUNBJmZaMzNS7xqQGr9648UAY1KVRw59x61 GwtR9039pOm8NIF4rTW/p7x4NiIkorvn/HLn IhR6OnH0llLh0FO4bmVQes09BtfpLTq03BTe2VVms0Sh0xm0o1 R/EwbiNMNaqs/CUNXR1I8vIEhCgYaS1yFkUreoxT20liP0Up6pB9E6NnXnZrRr9 DexmRNsjUFP2nIv85s0msN1jfBCzqdJvlNi16XdH08yQxnpYLJ KG1adgYq8ZokMxZOZiPITHK25f5YmTUKA0FhvHTry6yxG/5zFJ017v9iJFOdMdo9OpEMNdrQ8JVb1165/NWNK5eNPZMTWA3 /lLmKCRzfffNcYrOHPOn0tqs/3xjfFhzr58ICt298fSg6FJsYbox8RqtG7 h16uz/Sa1NvlPphUrr1/TakcH1erkLJ16fCwR4nn0BgjPn64majRjXxlp9dh1rSEx02/WrrmRutI0fB9x76DA4kJHANxXqN xhV478UWiUT3kf0Wn6fGn6DXD161dWdcnNd0TGp0R2KAdH9Ma9 eorX k12X4zZdRm AcBIqDQZvpTtT/xX6E193 4ggISmQGOVQbw6CogkZFapafou9FoRm8iLyZHNQbNkN o0/zcn0LRE6NZWdbXTJqxMeXDtePXNID4KqC46jdB3WHyj2q1aAsN 2oK67J/sXvUgXuhMP /OSrJAoX8lzTqc9PM0Oj3Zmqx98 6INwbYOfGlGm1h1AOKZEp/c3glZi7q rgWE4QBbQGIEcXv8ec6061RrWb0OqXYgtJm/sl/9UHVry5pwn8taSjLYBgzZYwmGke6XllhTtWMWe8OKYhUuKcDto DgAI9Q1DiU4AZIsl/6k6Hp0BKPGPSaEUBx0W/RGmmTf0ijHZ2AUtwKKMwmjfYq/N4DPPLK2OTvTcOXTfqxpIwvKfXg BddKZRx6Ip6OpV1iaM3Id0lIi9WDvp1dGK2/xWN9pz/qkGTlKWx q8BjMFkzbUJtda48soNDZV0azSRSuwBFdWOAJH1w35zYtdQYqL lfl2dg0I3dOmceXgskx5LsoD5Bq 8MTppSTJfm14U0aZzX/kvJRuzbk1m0Glj/i5D8qj/cpqeuuK/NT6WQWsH/f7r41k67UX/6MXk9Ov nlc0GTevpmWPZwAx1/lvjA5f8o lmf2DqWND9 kWoKDS015LzrzUk65DW2gSr1xOTEzpSjWNWafFNZ2cabVkpxrf XGe10BarJdOY qblzQxoddIudhk1IFopXRd/CgzVZQ2adFY4YY2OMp4b7DFhHqbShrppU2aKkTJf7Mq4XzwJOy 0Z2kt /xB1LcUyqrEMWa1UUpYpsfvL6adTmNkpnQbTuxYrKCidUIxBwNU 0dOUg4GribnwgJ6BaB8osKMM0ABiiD578GQU3pr5m6br4p57k7 LQMi8ViNGWkp6Wlm9KyH5QXDfq7U5QOip/AzIBRr9w/6DA84Nk9tkjKyEiiU1KSzSnQgaekJieZzUlwS3l1umBgrTWt3p pVDTXbg6jWy9DwQr9Ok9YQekMs vBxurKjdTUatCfBARLxlw59LwosGWhifZ0i4GTsO3d4RlJ3T09 3T/dbFj2KpDbtZvdDSs7/FxSraBPOSdyel9AFrE5Td4pq2mj96mamxXpuZKIb29N1/ov3Zca/CAVlvnZufGL6cR1v169PQEzdcXni6A0t uQN/xXg iqT8i5BcuekALDb7DHc9fAQFAbNW/7kG/4HHdAd3xlAQxTcaEzs8meDWJPmhgpEolYTyGVKsNIaNbrLAGFJ Ky9nIBHYQpPlT/39yK0b169P icnJkZHblwZ9391ZWz8LhRGBQWqqP8apTdmQPWiNXd3myCNUOs GragFlGUwDcajTD1dadixmbvO6WmDFl6aHw4DbZHlN3Wbh8beH M72Z42kZVvSukz rG64e4AtgLv09VvGlFH/W1oqezTtCqbQq0PZk1/QlHm4e9SfraWTx6zdk2to7cWr1rHJNZq0sXUXJ4wPLckVW6TcG skas94wT667lTp51eo3j5snx1MAxR0JMkzZAsv8JE2q/y2NbjJ7BXVxjfrq0IoVqf43dbeyEtUTo1r1yBcrEt/KSMwaW7lSc2tk5djwCnX3w42hoDD7r2aNWfxWy5DffONKtj8VU SQDCv19tgAU47eM2hR/j0Y/MZGsoeikW8MXBy/f6qGsei19fUyrueJfB3U5NT7WNTR4Y0Q9eitd 4D66kG2ABTp/iuaCb958kqmP2Wy 83uu1EEKj6M2ZtjFIUoqEy/fyQJ6s8sS4bZqNMlvnJu8MYYeGTSfy1DY/JfyrCkmmgq7YZ/LPXh4oK8yPZP m995f/K77 B/ EpPF6bvHGXRwLVL5y zp loREFFP9X/RPUW1A8QOWh13aNv6m9BpWfxjh4059m8r ViBMKtMZ06datGT1Cm0bGxkbJv7FRch84/jN5ekNIai0oo/Q3RiFZm/09arNZq 7xZ5j9Q4mgcNrX/JmJmmtjaqOFUpv9w9qb4zjNoTVlaNXp/ovqh2kGoliTtIoyGHXGJEyItEEpw1 B5mN6g0Anjt2i1Vo6408jUOOBvbNWWEfVapM/TXPN323Qd6ek QfVyZPXaNOYSa2 MbTykv/KGtr6pumaXk3d7Hmo0qJ2/mSw6403Ll7svtiT1TWU3nUu61x35uDguXMXU6dN/pov3oQqClofC9TYdMqwfyzDODliGb2kpZOu W9OXqTpL/1j3SP Yf0X162XRiExQRk2OWLSjl1bNzzy8LRLspnRZDQak0w41WkyJs FhMuH/V6axgjZlmH aBiTUQHGLr5LTzJQhswdpR61Kz/qpRkfTVovGCOUXbemxUDhHbc7K0EKCXteTMbN2Yj6l9bpVJKWT 9A6tCE7s3NWPrNKSeeGphl0LldMdacYZbngAhGSdQqtWQkJpln UPnfHBQ3dfn0pG1k17fvt4gGPvyVqGqd8w3JXF7p2Juv94YLf8 F9dO/9XjvzGKhxy3CQtZbZX LsB3Tbzd99ww7c27fqqbGQVNrfqRfhVFr1IOatXUkx9RFHTU5B 2oUPEE4DP5Cd7r75xJK /c/kWK pGemnoKBe6P4AX1cBT0mo8uf/ enPXv/009eV41M4Pgo8X736Z6 //tFHr//sZz9T3vjo04/ggMd//uhXn/4KT/23f/vZnk9/9at/g1/E3/roo09f/3T13/8veI2nvf6z11f//Wp49nAUq15t9xQEN Tz7e1ej8fb0dnphUcP3MntshwfnSfL7e38vza6JKldgnO87e3t kiyd2Hgiv6OlzXOmLf5QacvZll1NHhF 0i60n2gXvS8 /r FdhFfCUJHfjDv8bTMiIK1h6hCjnGcwAmyzME/WRQ4jpMkTuIYG7zv27Zahjc4J cUJEGCR0e5cPDJ8uaONr71uZimrXE7tjMc5xY4luMK7Sw7d4cM z/AD crKoqCDEtc8EwoXy aFBBVKkixLAEEEEDIMJQMMSYDRBckXss0HiDiEIEkwGMeKHa37 jndc I/TB7ZvOPv413/ZIOAhsXZBYPNi57XACw7f4Zjiom9s9XHcLFAIqvl2MAQCUQ58B uMScwAwvBoJrSAhMhiMPXu6xeWSPR3NB/KLzs57jLeTQSUmT4SfFx6 IO6Nhdey0GhnDsZVyoL4cBTUqwKg2BldDI4gJoDRZZHYRZbIsJ xcHMLi8BInkAeJdXS0Np0S8Rdad8fFF8XHNNjxwlm5IN9LjNLS sX29DI88wzDFgigKwky2EDiXwIcskGQvN2UKgkIiXIAn7r17fG R0J/AGgG2okC8c3t2EJ3V 7 vz4koKPmgCS6DdxNaDBIVLYFgYur3hmN21bKfMd8gPRaEDFKwg iCqVS5RxTE70yl7FK/DKB3cSfKaCQhLROszfCr/bf/o/GhFS75Kv73 xbceSEwBcFMUzvwwKRRNAaPC8KDa3NDAn2kND2z3yw1FgjAiCv XjDUjuOjNYgGCQFBTIDLhMp4kRiADF9C779h92qsxcAhCB7m4J LS0ODtyKhkNZxcQfArYLogivbFdNaVGAHW4R6GmZGIcLlRRcXi wjBKxIkoggwMEzIg CSlDhFWnA lcoRFHq2zYVg25vyT 8O2gbuAJzoCLlDEAV0hiAUBcfHxwp2Ye O1tiZUFCvtnOCfSkDA3NeOcAML4eBirZAJCxyE2MEBpZYKa wMKjwTAeGsSzHquLbJJ iDcgHlyiWb3ZAcMDr CXb9/J2 94Tp2NmRoE2V233CAFmevG/SPyhSJjMkivFa0XanOSE QtYT4dMxKNyyePthM8imFRAYJ73axEEyzKH84sY1u6av7NNNXO MuMDSeTtFAW3hvY0CDdENNx8nC6CYGAPkw8XiRi7PJhctwyiCt Lm WQvoZJI NRc7kCxYlk2JrqNZ1ibK/R7Z/ez0ozsBF0uKAaPQKRy HleYgtCVo5wVXBigFQ0yiBwHlB3OE21zYcn IqDXwy4kUAR5OIyBYODjYkpjXUgim2eFm4GFPSr7U5WsDOi3Nl 2yWyyHWSD4eQ8MqolnDZx5B3DiJcgryTDC31xgUfRqyI2UdCq7 xGYJ2Iwr606cUnXDabbaeNh1 a2RaoGILoDWCAx074YB/nI5 sGANVtR1Q8C6IVgmJKKIHfNue4AOs4RT9r/mFU3I7wRT24tbH17ttrI1d3yrPgp1OGAQUp3OKFnJnpyjfPvAS BdbeaRc9LkxWRCNlHuNGcMvbnixjfRjIeBMkWajJrXUDNeG6 NZ5FSzYYvO A9IsUADnBA/vQRRebwDGHRRecLavcKfgYEWvy UW3HDpTqkSA8ftlOO tkmQSPrzkWKgrJwRhXqWdTUWtB6a62BsTPnRvJ3emWNERBRCHk Po5SUs61VsgYre2Suzos/B1gp8e2WxELjmhngH/NztlvfOKyJnBhIfV10UUljOuhzshmjPvFCX3WY7zu7eDp83Ewq IP2dtWTEP2atT8UknuKSXU QCHtyCXFv9rucMH7Pss3o4S B8BcvL61mIXLG8bC9RWSXPSFztnpDipftYhy0kruRbewS73Xbc EXMQgm7mPCI5ayuKRZfsm0pknWeIkHO9vYT4guRwCLzcuHSD08 YdYyGl7H3eVu AURvLcvbICgpwE9yc1cfFik1254no/BfnsZydtTtsxaBFM8cIsJ7duEFwyAovvMQNECNyJyFIr/uMI6cgvlmICymWKu3lyMsDu1i3ExhSnrORITKPCQbunI7q3Jp6 h8seOjf/ubmszQ4R62Ahwc3ITqyOyo822Z0wqFJdwOBELHq9XnCMj73QcS xmu2d78G5XO4gpFhrNp8tqIVx8x3PeQ1DITKg7Jal S3Vubq3DEfroPNWSuEIGQsQlQM0wky2oV FChGVLNzAiXjfcgBwkRnqJfsO9mz1THH2k/YV87zEeHQXDzj9YnQuXKDuqagJ1oA9NIdXnlm3Zkltb8c3Hdqn iD8U32myNoFmz8Qh8KhsUx1R2TIWm6CXhwk3lWKdLZGKbPYyLr XVDOYhF2dxiWxkry/bCunoOxvcRa7gld/WWnNXv17DM1 Z6DsTEt9qBF/ZGD9Zts6gvKoP2t7V2EoUCt4jEFiRAkJyQZsCwYvPGdiAwqT56 Dz7mOL7ZcZA5tt3n5KYOH5B4i Mss6FYFnYWxT8RFLLTxkLmOVHAz iRVT8WOflg0P74zzs4LiAYXm8nVBi9QAtCD0FgljJy8YZOyGo otNBC9zVZXULFnxW7BUU2USnQDCVN31 etcLH/D8vvnz/3ZuMSR2B1scAyhmUq0fg9cKg4pi/uV3nLcrkB0BRS8xRq SqirzL4iFe72okOiRg98 8LXilk eDIViUUm CjqfbfP7OW1F0THNzDshX3uita3CZnPYj6l2eGeu GCwwtCWuH/t5BSfYLSCLWRvr5cjxpCEC3/k2UooZ5V ReLb LnLdm/Zk8eW2TsDqQaAiHvey/3Nk6rng3a3FL4TPbf4j8XlDpuN2RcaUtk5Mzs5zlHyYtEZearG QVtgVgVD93YTJ/2Oh QkugQ0hCTwzWcOHl9dUZPrcLzfSJhMYHAhT9Rsev/v573wfGnTiZC5bf9xusJuYx2u/OeCDvpmziOS07k7ZC/fPuUOolYQpCAVveQdsUP2CMA00p0Idr7N8URcVVVd1eaN7xT4v J29vb2QCX1xT255t8G 9QDT0Mq7tsa2lC5z2FnbUSY Otg EztpklNjtn9QLAZAkKR6gVMuEN7xQVHptnPszrko1NA2xJXu3G Cvr6qrW73giV9CvdfbeaYXWn1m/T X7d/NMjZHu8DaGPHFICgzxLZ9G5fFzKK gDxiD2luaRUJhIAtfscpQoqVjtQh2EU7wywgCUs4EPyC6ptP/qa 5pPVG0M4n0JmkJY9jy4of wb6ytskP3ZtzfJLwWxbO27xzdv3MvPAgVcoH1ukdcTQIEdGSDg uE6iHphPOoS8ebGMXSSFH9cUfCju2yXzV/ m r3Ny0ix58WYrq9Zv6 d2Ri8Dwsxp80mtBY6HLay9ze/t6fZO4tsxknuufEej4dER4AWMnpE8Qk2Gid27Ghp8ZD6qr65JP 7x OUhm4AXVTZJycK9XG11XU2FXJ 74Yhqu8CWQ7Ul2lnWtrkmp6yGkb0zx4gguFXLm1oRhW8aCgwOg kSUt 5vOBD3UjOLKcRR63lcpXrs7bqa6uoqpyyyJLLqq6uq6utqcsvq l6qOOyvWO1mmBVA4cqpzq6o313pn1gso3aLjO5rbgYhoW4DRSz jBKcWGT3QsiItvaT3AO7GUEBmmpKQ07ugn9fWf1LE e4gdA8lZV1VdXlFxwJ777me19ceOCWzBi3ug/szJ3ZxblVvt886iWxY2HG5p5qWAfk rO0WQU59cHvqtF XmHQcKce6iyX606Uhb67Hjx22 mtpfFz9XjMWI5Kwq27jJZisrq6l2QGqvF3cHObAh8IU kQtmmhkFJ7grD fvbeSmiIEovGgLcBFy9cRjQYds26PXL8NI3X/6bJHqQOPhkmKmxf3Orw GCCTl1Vdt2bI55/33wUTQtTgcZ344XwIUsqx64uPc3BrfLGotyaZa8kIjqrYcKMK9 nDcgHcAQYe8LpetVuw6oXCBaO1rP8iFz44N25x39oGmpbdvXin tB4QBEVXXVx6uXQnpncQ5ObMhz2FzYupZtqapxPtwWBsUjjarg eY23 xHiEe/UC1StUn5B8JKmDTbwCH/6Al8xN1h1oKK28dCxj6vnxkhcfb2ztmpzWd3HT3zPx5HmXXBsr mHspGOtf/ dXOcM7PzRjwGFW3g OOQEFjXdXiISnQGbkNQqeMQi29KQJScZCBLOfvbzg5s/eYdp2aHyNjWUfXzi87MOzumrr6r6uO43bzOork634CrLab5gr2 FZ6FnfXZ1bP4sYARSHomNOytiU9qIiE2dwihBgT I64qh7 /nDArhZWF9yurU6t27L3vz4/d9reSGk6Ifbqmrqa6uqPqmqqatygCmcblYqmCvN 6GQUy84ne6a96tn7lNFZH7880XNXC/EJoQq6AWhqQIDAsXDHyn/9cboJQXYhm04cuECk7Nlc9mB5ue/VZD/3I64vdVltVWf1NXVVdfVYcEjcG63LXbT hL eC0Qo/DJLTN6hKiW5Ip/fr/AgVoAAqD8xQ5R6dGgP5J7XWd3766tWb8kZCtOpBTyRctLmPnb7 Y893nDsyPKYij1FR49WVe85Ciiq6liZTM8KwvF3qqGdY ySb9nfbvnY2TsLWwifPb 89GQvlP5ITbn3jEjYiSEIyV3smBf32WdFIbvtUOu7bUdUIaVtM fsr3tkbtPqz5Us2HNn9zup564MXfFxVDTiU4k8Sjr /GbqR9esl7uDcLbUz11oe CVb/I5dAnrBR6KD9OykesGOROw4tGvXvIKQfB6naRzbgw7Hv5TvaS2 rXzB/QXNDyZFTMRWbnsx57 NqcEtuvdIqCjWfVNfapWXz6 vZo 9zs5hpBPRs/qFdZGDMIZCosSvwdiq60Xui6UJLyWOhyw7zDCv5KmKC4k9Fzzv S2lr mwWPHnWU8W0t81e/V4X qKuuVeYyOLbmk3qhsXHuk7msUL1l5hocUcAlnmoN1Fl3UChVj9 xbuL DFw4FbTpSsLdRlpi8 aq4U0FBITsqbZvfq343913mTFxQCVx8Xd2va5wQItCtcq7cLbV 8R8PqnGpWLHt/xvkLks04p NYCQ4JLOiEGq7lZDfWWJ29KOq9Baojqvhdb7/H79qAznvPlRd8 tT6olLVL5nc31TXfVzjaomPL/8FRqrDySnTT25bbo2t0p7z9jGQjlwYYRbsdLKeQl6p9yCdenub m6aiFPow78GYvfvj336naEcJnOrbE9vLFjW0HooviYvd/egTObm5W2K3Nx9/t6amqqpMZN1uN0iE4CxeWsHH8szSQsFlK3PMphOAVrtTEgMtOz qkuZVMaHGkxOA6mlqbmBhVa1wltHGSLeigxDM7gkJ3Hik 9uK3tzqqc0KCtzcee7t88 Z3oHN1uzm3UxCKloRsb2ggM2Z2TGqzyGYuVm58QVBqCwTTfNJ3 ez6JEy8caA2KUR0C5jiAeL7QUB8v7wgJCTnTyZz6PL6YrcnfUM hUbLKV1eRu4t1uUHD4zzLbNzQyTie07AjFPmP1i0V48 EYpexECZc7PD6l IUuketotbNx /NL8htEBy5MFBRJgrwtZB/jEj2q0JYjbWddrhfWH7VV1NQcXxZ/TBags3C6na6aGrvEOl1uNwtc4We2BSf4tobmKbJN7s4o8SGTDr GjozLWU3JYFdzcIQL1nGRNicljIXsXqZZu2HG4NL5w73tHHY4y x6bnQrbXuNAWUFpU1zngweVmIb7FWVQ5wLllcbx3qicCWwRqPW zaOc/ZFx8vVZUEv9gh4qqAEycbSWMqtO76hoqfd pU0AbpeFlNbS27aVlpZ61EpkNdbE1VLet2QrHR JkwKxQCd6AF2NklK9UVyIUy5YiVFtfSevil0yUvqipbOJZEISs zx8jUSVHpjlD SOvnwRuPM7VQ5jnetbk3H2NYJ4YJC8UwThywLN8uzDi79mOcy3 G2tuE8OBm7k6ySQH5Vuk uucOT/0HRc3uYVg70SBDqBYkJKgR9dNpaO90VlZXLDjFlb f oqamuuwX7x85zdtZ8ISzJrfa4cZnx/bYoMOdhWpJ3P7SAAqSzkSxFxMseSUcaS3epwrJYzbYAa3TWV/b0SmFHvRJnBuFwLaHtdttHz 5ccu7ObbjZcJL32ZcLISI05Gby2KwOIs3QMv48G7ZQPRC4HbsF 5Was1eZXyO1BjrEJ8Qc3rdph0q1twBoAcaoq5e9QizHODio6hy kiRcktuJYxXHG/q7NFhd0nMWxnWx1tcDi5LYg4gT6jHN8OE144AjOXgSmvztFzuf zBtjq274rr6F0e gxD5F61rEHB5VUeyEHlgVmWwW5vux4WVnZnvXVcXF21kkWBWpq wH9uXE58oVG2zWLFSrZ92IIopiZdO5UXPuyT5MbS JKzB3Z0nHHiLC9Xu1HAxj240McJHmnqcP5i06Yad1xQ7ZNfm29 jcW2itqbaSRZZ3RUhe4X1s5gHl5ilvHfakgBJIT7iIQjV06rnC narLsigEBK/razOeYyRuK0slFQd3BQKrr6M2REXo3L orCh3AkGEGp/AShAOznWuWdf47LZoLBF88rMWqd8uzO73Qo0t 6qzD9wwQWXJlXMXVZWO3 ZRNYUWdFJpueBBZCLauO sd1Rl2vvaGRBMwVkJ7IUWOL zLV0JhQS1HGOmFO3UZApYFHuwpUKH3C0i9t/uuXChQsoFk5H4dwKZ9kmu yEnMV6YHiyKQDu5fp98wvd9bVlDFmzYGtyN6NuQMC4XC6hcOZZ FCjjOk5zgal4xCEqTaIi6ZxYcPhUa8cFnH13QidQX/dJjgNDg2M7ZKfiDzCIVP9uoU0oO1pLVu/cbPUnCi/cHK6zzjivheuDjjMdQmApkKxLEK90EmpwMtdS0tog/q4cL9kp eLeya2DZgxXQxjxzpqExOVsynEytnpWwlpLsOWUI0bMsBiwMys 4xzk8Z7EFmMIh3z6g8Oy1Xzhd2sZ38GThznnwW7F1dVV19U7g7 7JCWSkzyU6JmupcJ9nugEHkchW3KXM/Sss48ww0WbJSxiYmCKxNYkaB1N4bu0vYeEAQPOS6ucplez6uqp cQrz1oj4/sTpAICkfuZkFZb4R7tyuH4V0CWYedGQVNeCFwIunJOgO9MoHRS RZquN5lz89dXeCxkz0YnFy 5RPQI1y09Bbu8CCXJGX V6531JN8qgxbXl7eSF4gpFnwAosGztOpFDleEZ6ISowGTJL3XH BeUwfrwU93CvWb62o ricrl5JPkKctLDtrOKLnKOCgF V24hF8CUE i/URyWn3TFU4XrLzwHuHGjJzqKChw9PWZiNbH5zRcc4yn08O7ExR pnwUa7DYU0i48M BXuSwUyhm4xFEIVQ2K426d9qOFOXgOPGPRSWfxzOfHyPFhXTw8 aKgD1GulJVDxCCS5QRJ7MBByS4iCIwcVoHAuWfDTjKVyHkCMzc iqYDJpCdHii2OO3OB fylaM8fzjgkF9hajnssZI9sV5YDcE8V9Acy7jiQBTsuPBMmAIx mvIP BLOK0zVz3Yl2k6dKTYKCJFdOYQbXeXr588sPlXhkhnUwnwmu3f M21NULItnINLXwSjZjSA7SsJM1G4f9NOg3VDmcG7TTNUNmV6pf QUB/KDPhOLLIyVMT4WDsw0uWLFcVC4VFIrOHFezxXh6XZCTFdeReIB P1EjJBUKYwyjbz0CLhmjxU4S73zLaAC3DyntuNKbEFRxaWcQwf 135k9 7QApYpZkngFe7HH C qcC2BLJlivvBD/7xB9/9wXe/853vfv9734n897UD3/ XH3z3H//9//zgO98N 973fzBzHoGEKHQoIDhlnrFZyaqKNdrb2pqYX69fJpAdY4KwV2l FYWjBGzAHJ598dtHiZ55d/NQjc54J64vsH0iISAgLjwoLDw/rDw9fvGjRbPIIa2 Rp0dH87RNB7LQ0tTCOIqLcIMd9MHMMknZPSYENtGgbsonFz8T/uzCpxfOeXpxRP9AREJf MBARMRAX8Rv /ueWfzsd2ahWk62sRlzaGAPhnwyTlB2r8lods7T0lHv6C1y4KSr 89dH1xPNRu1AWnIkrUsnFy9eu3jOwoWLFkeBJfoiEsIj sL7 n4bGfHbvoSIp56dMY9gK4WbQAK5DLxyci6POYlcKCcLIm Tyy UOpAL9bk5m5CJZMuF8kh2IZwMWxwW/vQjTy2OHDgfHtUX0be2L/x8X99AX3/k YG f5jRFkoeafISqSCE6z34bY Ai N4gxzGF/Ds8QsdaAu5Iuft9 pYXE4UpnIp2e9nf aZRYue/punw8MG1kZF9vVFRPWFRUX0DQxE9cMt6uG2eJmsFUncyTivsmO MrEh8WHLWHhALvLfH7hLL/9hC9GNfjp2tr99bCABE0IwAfyTpZHj4MwsfeWrRM5HhYXD9EX0 R/f1rIwf6I/rPD4BNImbRCYDEHUQUU0i4lm F jD8BLLl0x79aJz8r4U4GrOnDreALphfhzDuMNh3Miz8qaefXdw XGRben5AQNgBB0oex0j8APOkPf2ZmdqLSiJ3YkgU0gmv7HtlWw SlyJOz95g/l4r12 Eneesyj8tb/kVOH64lIX2SF5Du56OlFkeEJAwMQHP2RMHB/RN95cMX3B/rW9vf3zRip7chOYFhnQDFwFM8ZqR1IgajgioWm0CZWzmcAE1td D6T07fz6/DJbB 73Q4Ohfn/4yFORkRAUaID tRH94X0RYZHhUeCXqIGB8zPwQkHBuoTbCoTrcaLYgjsqyWZXSF jCgd1n7R4PWU2trQFC9u589NQfoFIVlf1qQG7fh4vCkRBhCCQq Iaq/r6 /LwLNEhEBHHn2qVnslCIoZGXTL qEyDeTIonsAcZO7PCFBkYsZryS0NjEc3Lnwa9d AMYSvQEoluUPgSlDF/bD6HZh8MCgvDIhPDIviiI1qiEiNu2CGxsf/nlux7pV7H5xP2YpFDAekWU5MoSnClBuUa5FBqahEpe4DdA HI8w4HK7mjtINOkIkntcNrJRZHP9qH510YNhPf1h68F9/RHRPadD084vzYy8jY7X37Q48ukTyUoBGIJ3GMDeEqxV0NNBG6A pPHRTS1N8kEG9xPW4h4zT tO3MPICbifBplxciHEx/l CImEvrC14A8wB8QrYAGjRESGz6EfchAUrJ3DqThSLZBSlrPH8F 5gPu6elblGoblFtb25xdPAoFiVzz99RjgTt0AO1HOEF8DO8Ij vvMJA2vDEyLDzoNuQaRERvVDgPTD0/A5GRnpGenp6RmBx/Q7jxkZBupVF tgOVbetrOXMIMQ8mQ j3jAN3C9Lr7Z80HwCy VeEgWYx7dfbaFf3uvSw5UlRCqrPThI88khIef7 8Lj4gaADxw X1gi74ECJkweHeO4SEHxIibdTgqOTk2tlcgHQcML/BNuK6pFFCQcsWOOJUq6HAlaXnYOFXT8Y37DoQwxBm4j1Jg3R/ 3VN9kL4GBjA6IVCiIsMhsUYCUTCZ9D2LHsG/1PMy SIPRdF68pd76JfxPWVXOjPfLm NxcyO2 LhEht4bFFk A/sA1N0NLVsVy2PZ8nkXcfzB5mmZs9jcd6pfgN48eGcsLBFEQlRE eERaAEIlIiECDz6w6NASIhq0foUE5WsM5oMpiTjqmQTZUwyUkb TT1bRNKIoDmJ820LJLmaJsIHn2wWl64IXEJxFTU0d 5cvz4fuW6g/E1/MezzFj21DKVF6IE74cM6chZH/ANVNP2hFZBhAwaiN6E8I64sK7w9/Gr/pZRo0da9bN5iRZhxOSe1Ozsy0dA azZfNQ2sIisq5gGJ QC1w4K2xsrLxH7cR8w0HQvfPa2g6tFx1wiW4HfIFQW5saJi3VR bkqXYDeDEnfC1Q4vxAOMhEZBhwErR8LSjY ai1UX2oWuqe7sSkkcTLbyXqr5gtlxINw28Mdpl MrSyq/uffowxUsh5t4WIRH5wZFGlUoiHVZ1Qua8odPfXD4qtu0NacVKX 7RTdsYfBYHgGT6a9IUb Zs6isGdAMIANimpFne9fDDIOXIHnYYBCa72UmDpMWUZM9LAp7Y rGdHnd0CVT8tA/XXxD/WMe56kF eBc5KKIigktxzKhXWm4BLunaO8R1ZFfNpScKglpEl1kB6mg2g9 3Ho8AXYeI iZ/OOcRqPWeWtuPig0k/QfIpxAj4JSIyKhAfaHLSrMmWVMzzpkvG7WZGetSzD9P nnGxVQLDey0u8hVFYvtuH2Y5PP9sfaGE5DNoBjPa45bz6v45kO lpYfzj/CIAt5uOpx3gsdDCMjdyTmPPLIIVTshIQqEOxIitg/iY6C/PwHSStRiop0aIwQHpaX0 PfbDLSWXkVp4F6jR14oO8pBviEpCMg4sZln1kMmh FsG5qW5Qk7xeLS0tL4XS3N0OC4BK nc15QsehpEm/z4uQcMMazYaCcff0JiwEG4Ej4LaSS/r61kRFhi8h3 9OTLK lZaSCXqWmpaVlJBstlrT0tNcy9KhagaVxyAknCO0FsamgMo8Xx XZRZPKaChoBYdOR0kPPlza3t2Pi6zxzInhuc0dzsyAGdEv6cCE YY84zGKKQwfoj1g5EhoFHohL6 8L6w6LC55A/tJOUkZ6alrIuw5puMZtTk41pljcs6ZZ1ECONdpbEGsd37lwKbA SFEItiTxzgyQhMXgOP8xDFy3ccjj/lEQkKwSNEh7aLfKPIFJMkCLxYOOdvHpnzdHjEWuhDwoELmODDI wbAQ5ERa9cqvMA/KaXHP4OiU77bT76YiN/2BxTINx4/3BMb7cJvnAhyUbTicRCLohLeDj9sWL78cOupVkFU5uzkrfPxN8 TGRrIlW w8OWch GThswAhMgryWFhkZEJkArQmUO6BX6ICf52F1it/WYBWQN3 K0VrGgOu5XlxGXYAeGWVsfz2YuCJx9PY0Gq3u6DQbYqPLylpIm diOcLjV2TwIBkPUcx5ZM7fQbRCrYMlxuIIqDCiQDYToC3AbIbD mvALsrTpFRBR8idWdIakVYFaqylw1UKjJzSokhBDlPnW57byYm dx7InmJgLTJRzOL1m m3iJRSYTLO1oCXyPO7lw4SNgjqcAR RayGGQykDMIWahzIB8QmpwOu0Na4r1jTesVmu2dZ0Vj2xzmtWa odOvaRJ51o4ZiffGhdhFtIXACK3LQ0LbG6KjC4pVDNrexR/5oHT5LhzRLp7xioKdFGgCqYzgdnLONx95ZOHTixY /SzkMpAIuEFqfwmSPdQdii30qakpyT81p6SkJKe/lpyakmROwxdpVppe08SSQxAONvDFIqmvmOjiXSFLgkPy50bn5w flEUvFBec3NzSJUFiBYHg6AvZDj C3NrwnHyH0XPj0nEXfh QOzhjoDwOLgJRDK5Cg9CM68pVA1AwanuIN7lfpDXrqp60MVDkc z4ohMZ6p2IveHvdoaL4q/rHogg Ct2MOE KCdvKNbR7uJNnETkiMN/w6kggVPHgEQxU61aefioiKHFgLDIWsCrmtH9SrP3x69atEyJ3X NPCiwebABU eV 1sBYYSY zbvku1o6Vl TdimltC5jciA14MbmipbG1TJlHtBABDcJCvYnkhm82Z89RTT6M xoNwBzRqA6gLUYqC/D3nxfwEx8jDbC7crnAAAAABJRU5ErkJggg==[/IMG]How the current West African Ebola epidemic is altering views on the need for vaccines and is galvanizing a global effort to field test leading candidatesMyron M. Levine, Milagritos Tapia, Adrian V. Hill, et al.14 September 2014, Advance AccessDNA Vaccines Encoding Ebolavirus and Marburgvirus Wild Type Glycoproteins are Safe and Immunogenic in a Phase I Clinical TrialUzma N. Sarwar, Pamela Costner, Mary E. Enama, et al.14 September 2014, Advance AccessA Practical Treatment for Patients with Ebola Virus DiseaseDavid S. Fedson25 August 2014; Advance AccessReply to FedsonAnita K. McElroy and Christina F Spiropoulou25 August 2014; Advance AccessEbola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical OutcomeAnita K. McElroy, Bobbie R. Erickson, Timothy D. Flietstra, et al.
    15 August 2014; 210 (4): 558 - 566Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic FeverLauren M. Smith, Lisa E. Hensley, Thomas W. Geisbert, et al.
    15 July 2013; 208 (2): 310 - 318A Syrian Golden Hamster Model Recapitulating Ebola Hemorrhagic Fever
    Hideki Ebihara, Marko Zivcec, Donald Gardner, et al15 January 2013; 207 (2): 306 - 318Reston ebolavirus in Humans and Animals in the Philippines: A ReviewMary Elizabeth G. Miranda and Noel Lee J. Miranda1 November 2011; 204: S757 - S760Management of Accidental Exposure to Ebola Virus in the Biosafety Level 4 Laboratory, Hamburg, GermanyStephan Günther, Heinz Feldmann, Thomas W. Geisbert, et al.1 November 2011; 204: S785 - S790Ebola Reston Virus Infection of Pigs: Clinical Significance and Transmission PotentialGlenn A. Marsh, Jessica Haining, Rachel Robinson, et al1 November 2011; 204: S804 - S809Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever ark G. Kortepeter, Daniel G. Bausch, and Mike Bray1 November 2011; 204: S810 - S816Characterization of Filovirus Protein–Protein Interactions in Mammalian Cells Using Bimolecular ComplementationYuliang Liu, Sasha Stone, and Ronald N. Harty1 November 2011; 204: S817 - S824Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat CellsAnnika Kühl, Markus Hoffmann, Marcel A. Müller, et al.1 November 2011; 204: S840 - S849DRBP76 Associates With Ebola Virus VP35 and Suppresses Viral Polymerase FunctionReed S. Shabman, Daisy W. Leung, Joshua Johnson, et al.1 November 2011; 204: S911 - S918Real-time Monitoring of Cardiovascular Function in Rhesus Macaques Infected With Zaire ebolavirusMark G. Kortepeter, James V. Lawler, Anna Honko et al.1 November 2011; 204: S1000 - S1010The Importance of the NP: VP35 Ratio in Ebola Virus Nucleocapsid FormationTakeshi Noda, Larissa Kolesnikova, Stephan Becker, et al.1 November 2011; 204: S878 - S883ole of VP30 Phosphorylation in the Ebola Virus Replication CycleMiguel J. Martinez, Valentina A. Volchkova, Hervé Raoul, et al.1 November 2011; 204: S934 - S940Ebola Virus Failure to Stimulate Plasmacytoid Dendritic Cell Interferon Responses Correlates With Impaired Cellular EntryLawrence W. Leung, Osvaldo Martinez, Olivier Reynard, et al.1 November 2011; 204: S973 - S977Filovirus Infection of STAT-1 Knockout MiceJoLynne Raymond, Steven Bradfute, and Mike Bray1 November 2011; 204: S986 - S990Host Response Dynamics Following Lethal Infection of Rhesus Macaques With Zaire ebolavirusHideki Ebihara, Barry Rockx, Andrea Marzi, et al.1 November 2011; 204: S991 - S999VP24 Is a Molecular Determinant of Ebola Virus Virulence in Guinea PigsMathieu Mateo, Caroline Carbonnelle, Olivier Reynard, et al.1 November 2011; 204: S1011 -
    [IMG]http://www.websleuths.com/forums/image/png;******,iVBORw0KGgoAAAANSUhEUgAAAIUAAACvCAMAAAD kM 1eAAADAFBMVEU8PTw0NDQqKioqGlc2HVsiFU45HmI1IV47I2Qr I2EfGVBCHV5OHmdFMU5HJWlMKXRONHRUKG1YK3hYNHhTNW9lJV dlJW1mK3hmNXt4Knl1NX51K2FDQ0NMTExIR0hTU1NcXFxWWVdW SFJdYF1fYmBhU15pVWtkZGRsbGxrY2pxY210dHR8fHx2eXd5bH ZbLINbNIRmLIRpN4ZsP5J2LYh0O4x8PIt1N4Z5PZJqRYdtRZN4 RYt6R5R5VZVuUoh gX6YAAybABSeARygAx hBSKiCiWkDimmEy2pFS2rGC6nFjGnGDKoGTOqHzioFzKsJDytK D LL3euK0KsLE pJ0atLlCwLkawMEeyNEu0OU61PVKsN1SgNnOVQHuCdH63QVa5R Vq6Sl64Q1epSH68TmGzTH 9UmW/Vmm/WWnBXG3CXnDEY3TGanvIbn7FZ3jIcH GLYWFOYqGPZGXN4yYPJGXLIesOo2oNYqsPpGkPpGyPIy0OYizP pGsLoaDQ42IR4yERJOES5SLRJOMS5SIS5mNVJyHVJiVRY2US5W UTZmcTJWZR5aTVJuTWp2cVJucW56YU5WJUY6MWaGVXaKcXaGYV qCLa5OcY6SZaaeUcaiqSIikQ5OiTZmsQ5OsSpasTZikSpapVYe kVJulWZ6sVJusWp6jW5K0QY6zToC5Qo60RZK0SpazTpi6SpW5S ZazUYGzVJu0XJ66VJu5XJ6jXaGsXqGpV6C0XqC5XqCzVaCnY5a 3YZ kZKSsY6Otaaasbaqlaqiscq2mda2se7K1Y6K1aqa0bam5ZKO7a qa8bai2Zqi0cqy8cqq5ea 2e7KzbrHAVJvCSZbKc4LNfIrMeIbJb4DBaqfCcquEhISLi4uPg YuTk5OampqYiZO3hretibmmpqa7msLPgY7RhZLTi5fVkp3ZmqX Zm6XCjrvco6zfqrPep7Dgrrbhr7jis7vkuL/KmMLEp8jlvMPpxcvpxcvszNLu09fx2t7w19vy3eH36uz15uj57 vD68vP//v789/goETh3AAAv2klEQVR4nO18e1wUd5av2cwj89m7EHE2Eq JybgzMANspCOYCBmU7e5yqrvTseMM0LNXIEPaTiBMfEQSnPhAf ICIjpqFHUXYojskPJIuGuyORfHQqq5qQO MQAOL18wiyoibyQx8xEFie8/5VaP4GGHv/HH3jyntJ0X/vnXO93zPOb/fr5mj/ 9wzPn/DYAcf0Vx5/grijvHX1HcOf6K4s7xVxR3jtmj0AUeDf/lMQw6OO76qLtf3oXinp/cc1CUlsabVnvX2zRFUzOAoDW0ftqwOviYe0 ZQkGv0sF/ci78jp6G4y7AtNlsNiWZU9f0XIUT7rxtNJtSHg5CZ7rSowlcIn wkbRwce 1eGFMojCajyWQgQyfROtpkMhkNhmkwtCOX141fsYxmpU0aAk7B e3rNpZuZged3fDX9lVGv/eKy2qhTnsNxNdlinnYd01FQqemp5qwMq9X6hjXTajWbsq2vWc1 3INOGt7SJ17pXJFlM1/VqLZiD1mpwKI35Bk3rtegncBf6i9bSahqea/DnlEZrVFrCaItRraoLGMrtT GY/o6KSkV15JTk1OSTXDv1Rjsjk5KcU0HTJ8wLVujYEy/8ncZaX01JoeKzJEC7ahqfTsdRRtthqM69Iok8X0Voopw9STvUq vfaXHQquHAYVOrzVZs0xa/eVrFtN9DJzyCEXpgGdwaLUUhaxYRVP3nAwo1AZt8o2ec19lqs1 Da0YuaQx6bfqkUXNp0DhyVW39ykSPjKkzvro0ZrXe6sm60ZXYM 5QxmbFy HIiDGD 0rzuupkaHn8ICpPRaKIwgpARD44WgoIyT hXDF9ZOTJsvjyq1RvAFnTqBK0x3kyjrycnZo1qtH yJlKmiTUrBr9MzDYlXstagbYwaEa7ExOHx1ZmjSbe/9EBFDRQ4k3LG9Y3jKnp1ox7yXMbBXrkOjh6WD2eaU6B0wDFDW3 PdfDQ9R56IkXdM6bRj6fTtGnCpL74ezWVmT2eDbZQg88nM7Xar MnEc2Pa z86gEJnTElNTUtNTTeak82mB6IwqMd6Eg1UyrhefWl45fW3Vqj xXfAIte6mXktNZOgnTSt PppIX0vT0qbrpsTBkRWjF1eMZoItEg067fhQorp7bOXPv/zzttBTgUOP5HigKfSmyWG9gbLcSNaOjCZm YfOAUn12owJPTU6TL01QtHXh9OuXF9jmsym6LQbqerhscSxEfP 1YXrkCwqMtm7CbBy1JA6NP8DhgRjRmYxwZ3yF0hmMJsMDeWGwn utJp3XW7jRTT49JY7nag28mdo1ARPb0vInRfiUztceU1p1tpK3 d6aa3etaYhi2WrOSenmQao6kry6w1ZZ9Lv/8qp3hhedNiQWpYjRnW 0RFObRqNX6YBlUBJEKtAbCrzMPoPw2lhReUWktpaJAIHegEpcM z1aAkoBzkAymIPr1Oo3mAqW/HSEpaWuprqWlm/Z/jhX6aZN558lMDfqhx6h3dPafDOyC1dyVA4wM eQqFDtMSaAamkAcH6r2fhulPq3kA4e/8 M69/r7nD0Qx40FrtDjmdDPptOk9f8ZuoOBTJz08Vf/XUNBJmZaMzNS7xqQGr9648UAY1KVRw59x61 GwtR9039pOm8NIF4rTW/p7x4NiIkorvn/HLn IhR6OnH0llLh0FO4bmVQes09BtfpLTq03BTe2VVms0Sh0xm0o1 R/EwbiNMNaqs/CUNXR1I8vIEhCgYaS1yFkUreoxT20liP0Up6pB9E6NnXnZrRr9 DexmRNsjUFP2nIv85s0msN1jfBCzqdJvlNi16XdH08yQxnpYLJ KG1adgYq8ZokMxZOZiPITHK25f5YmTUKA0FhvHTry6yxG/5zFJ017v9iJFOdMdo9OpEMNdrQ8JVb1165/NWNK5eNPZMTWA3 /lLmKCRzfffNcYrOHPOn0tqs/3xjfFhzr58ICt298fSg6FJsYbox8RqtG7 h16uz/Sa1NvlPphUrr1/TakcH1erkLJ16fCwR4nn0BgjPn64majRjXxlp9dh1rSEx02/WrrmRutI0fB9x76DA4kJHANxXqN xhV478UWiUT3kf0Wn6fGn6DXD161dWdcnNd0TGp0R2KAdH9Ma9 eorX k12X4zZdRm AcBIqDQZvpTtT/xX6E193 4ggISmQGOVQbw6CogkZFapafou9FoRm8iLyZHNQbNkN o0/zcn0LRE6NZWdbXTJqxMeXDtePXNID4KqC46jdB3WHyj2q1aAsN 2oK67J/sXvUgXuhMP /OSrJAoX8lzTqc9PM0Oj3Zmqx98 6INwbYOfGlGm1h1AOKZEp/c3glZi7q rgWE4QBbQGIEcXv8ec6061RrWb0OqXYgtJm/sl/9UHVry5pwn8taSjLYBgzZYwmGke6XllhTtWMWe8OKYhUuKcDto DgAI9Q1DiU4AZIsl/6k6Hp0BKPGPSaEUBx0W/RGmmTf0ijHZ2AUtwKKMwmjfYq/N4DPPLK2OTvTcOXTfqxpIwvKfXg BddKZRx6Ip6OpV1iaM3Id0lIi9WDvp1dGK2/xWN9pz/qkGTlKWx q8BjMFkzbUJtda48soNDZV0azSRSuwBFdWOAJH1w35zYtdQYqL lfl2dg0I3dOmceXgskx5LsoD5Bq 8MTppSTJfm14U0aZzX/kvJRuzbk1m0Glj/i5D8qj/cpqeuuK/NT6WQWsH/f7r41k67UX/6MXk9Ov nlc0GTevpmWPZwAx1/lvjA5f8o lmf2DqWND9 kWoKDS015LzrzUk65DW2gSr1xOTEzpSjWNWafFNZ2cabVkpxrf XGe10BarJdOY qblzQxoddIudhk1IFopXRd/CgzVZQ2adFY4YY2OMp4b7DFhHqbShrppU2aKkTJf7Mq4XzwJOy 0Z2kt /xB1LcUyqrEMWa1UUpYpsfvL6adTmNkpnQbTuxYrKCidUIxBwNU 0dOUg4GribnwgJ6BaB8osKMM0ABiiD578GQU3pr5m6br4p57k7 LQMi8ViNGWkp6Wlm9KyH5QXDfq7U5QOip/AzIBRr9w/6DA84Nk9tkjKyEiiU1KSzSnQgaekJieZzUlwS3l1umBgrTWt3p pVDTXbg6jWy9DwQr9Ok9YQekMs vBxurKjdTUatCfBARLxlw59LwosGWhifZ0i4GTsO3d4RlJ3T09 3T/dbFj2KpDbtZvdDSs7/FxSraBPOSdyel9AFrE5Td4pq2mj96mamxXpuZKIb29N1/ov3Zca/CAVlvnZufGL6cR1v169PQEzdcXni6A0t uQN/xXg iqT8i5BcuekALDb7DHc9fAQFAbNW/7kG/4HHdAd3xlAQxTcaEzs8meDWJPmhgpEolYTyGVKsNIaNbrLAGFJ Ky9nIBHYQpPlT/39yK0b169P icnJkZHblwZ9391ZWz8LhRGBQWqqP8apTdmQPWiNXd3myCNUOs GragFlGUwDcajTD1dadixmbvO6WmDFl6aHw4DbZHlN3Wbh8beH M72Z42kZVvSukz rG64e4AtgLv09VvGlFH/W1oqezTtCqbQq0PZk1/QlHm4e9SfraWTx6zdk2to7cWr1rHJNZq0sXUXJ4wPLckVW6TcG skas94wT667lTp51eo3j5snx1MAxR0JMkzZAsv8JE2q/y2NbjJ7BXVxjfrq0IoVqf43dbeyEtUTo1r1yBcrEt/KSMwaW7lSc2tk5djwCnX3w42hoDD7r2aNWfxWy5DffONKtj8VU SQDCv19tgAU47eM2hR/j0Y/MZGsoeikW8MXBy/f6qGsei19fUyrueJfB3U5NT7WNTR4Y0Q9eitd 4D66kG2ABTp/iuaCb958kqmP2Wy 83uu1EEKj6M2ZtjFIUoqEy/fyQJ6s8sS4bZqNMlvnJu8MYYeGTSfy1DY/JfyrCkmmgq7YZ/LPXh4oK8yPZP m995f/K77 B/ EpPF6bvHGXRwLVL5y zp loREFFP9X/RPUW1A8QOWh13aNv6m9BpWfxjh4059m8r ViBMKtMZ06datGT1Cm0bGxkbJv7FRch84/jN5ekNIai0oo/Q3RiFZm/09arNZq 7xZ5j9Q4mgcNrX/JmJmmtjaqOFUpv9w9qb4zjNoTVlaNXp/ovqh2kGoliTtIoyGHXGJEyItEEpw1 B5mN6g0Anjt2i1Vo6408jUOOBvbNWWEfVapM/TXPN323Qd6ek QfVyZPXaNOYSa2 MbTykv/KGtr6pumaXk3d7Hmo0qJ2/mSw6403Ll7svtiT1TWU3nUu61x35uDguXMXU6dN/pov3oQqClofC9TYdMqwfyzDODliGb2kpZOu W9OXqTpL/1j3SP Yf0X162XRiExQRk2OWLSjl1bNzzy8LRLspnRZDQak0w41WkyJs FhMuH/V6axgjZlmH aBiTUQHGLr5LTzJQhswdpR61Kz/qpRkfTVovGCOUXbemxUDhHbc7K0EKCXteTMbN2Yj6l9bpVJKWT 9A6tCE7s3NWPrNKSeeGphl0LldMdacYZbngAhGSdQqtWQkJpln UPnfHBQ3dfn0pG1k17fvt4gGPvyVqGqd8w3JXF7p2Juv94YLf8 F9dO/9XjvzGKhxy3CQtZbZX LsB3Tbzd99ww7c27fqqbGQVNrfqRfhVFr1IOatXUkx9RFHTU5B 2oUPEE4DP5Cd7r75xJK /c/kWK pGemnoKBe6P4AX1cBT0mo8uf/ enPXv/009eV41M4Pgo8X736Z6 //tFHr//sZz9T3vjo04/ggMd//uhXn/4KT/23f/vZnk9/9at/g1/E3/roo09f/3T13/8veI2nvf6z11f//Wp49nAUq15t9xQEN Tz7e1ej8fb0dnphUcP3MntshwfnSfL7e38vza6JKldgnO87e3t kiyd2Hgiv6OlzXOmLf5QacvZll1NHhF 0i60n2gXvS8 /r FdhFfCUJHfjDv8bTMiIK1h6hCjnGcwAmyzME/WRQ4jpMkTuIYG7zv27Zahjc4J cUJEGCR0e5cPDJ8uaONr71uZimrXE7tjMc5xY4luMK7Sw7d4cM z/AD crKoqCDEtc8EwoXy aFBBVKkixLAEEEEDIMJQMMSYDRBckXss0HiDiEIEkwGMeKHa37 jndc I/TB7ZvOPv413/ZIOAhsXZBYPNi57XACw7f4Zjiom9s9XHcLFAIqvl2MAQCUQ58B uMScwAwvBoJrSAhMhiMPXu6xeWSPR3NB/KLzs57jLeTQSUmT4SfFx6 IO6Nhdey0GhnDsZVyoL4cBTUqwKg2BldDI4gJoDRZZHYRZbIsJ xcHMLi8BInkAeJdXS0Np0S8Rdad8fFF8XHNNjxwlm5IN9LjNLS sX29DI88wzDFgigKwky2EDiXwIcskGQvN2UKgkIiXIAn7r17fG R0J/AGgG2okC8c3t2EJ3V 7 vz4koKPmgCS6DdxNaDBIVLYFgYur3hmN21bKfMd8gPRaEDFKwg iCqVS5RxTE70yl7FK/DKB3cSfKaCQhLROszfCr/bf/o/GhFS75Kv73 xbceSEwBcFMUzvwwKRRNAaPC8KDa3NDAn2kND2z3yw1FgjAiCv XjDUjuOjNYgGCQFBTIDLhMp4kRiADF9C779h92qsxcAhCB7m4J LS0ODtyKhkNZxcQfArYLogivbFdNaVGAHW4R6GmZGIcLlRRcXi wjBKxIkoggwMEzIg CSlDhFWnA lcoRFHq2zYVg25vyT 8O2gbuAJzoCLlDEAV0hiAUBcfHxwp2Ye O1tiZUFCvtnOCfSkDA3NeOcAML4eBirZAJCxyE2MEBpZYKa wMKjwTAeGsSzHquLbJJ iDcgHlyiWb3ZAcMDr CXb9/J2 94Tp2NmRoE2V233CAFmevG/SPyhSJjMkivFa0XanOSE QtYT4dMxKNyyePthM8imFRAYJ73axEEyzKH84sY1u6av7NNNXO MuMDSeTtFAW3hvY0CDdENNx8nC6CYGAPkw8XiRi7PJhctwyiCt Lm WQvoZJI NRc7kCxYlk2JrqNZ1ibK/R7Z/ez0ozsBF0uKAaPQKRy HleYgtCVo5wVXBigFQ0yiBwHlB3OE21zYcn IqDXwy4kUAR5OIyBYODjYkpjXUgim2eFm4GFPSr7U5WsDOi3Nl 2yWyyHWSD4eQ8MqolnDZx5B3DiJcgryTDC31xgUfRqyI2UdCq7 xGYJ2Iwr606cUnXDabbaeNh1 a2RaoGILoDWCAx074YB/nI5 sGANVtR1Q8C6IVgmJKKIHfNue4AOs4RT9r/mFU3I7wRT24tbH17ttrI1d3yrPgp1OGAQUp3OKFnJnpyjfPvAS BdbeaRc9LkxWRCNlHuNGcMvbnixjfRjIeBMkWajJrXUDNeG6 NZ5FSzYYvO A9IsUADnBA/vQRRebwDGHRRecLavcKfgYEWvy UW3HDpTqkSA8ftlOO tkmQSPrzkWKgrJwRhXqWdTUWtB6a62BsTPnRvJ3emWNERBRCHk Po5SUs61VsgYre2Suzos/B1gp8e2WxELjmhngH/NztlvfOKyJnBhIfV10UUljOuhzshmjPvFCX3WY7zu7eDp83Ewq IP2dtWTEP2atT8UknuKSXU QCHtyCXFv9rucMH7Pss3o4S B8BcvL61mIXLG8bC9RWSXPSFztnpDipftYhy0kruRbewS73Xbc EXMQgm7mPCI5ayuKRZfsm0pknWeIkHO9vYT4guRwCLzcuHSD08 YdYyGl7H3eVu AURvLcvbICgpwE9yc1cfFik1254no/BfnsZydtTtsxaBFM8cIsJ7duEFwyAovvMQNECNyJyFIr/uMI6cgvlmICymWKu3lyMsDu1i3ExhSnrORITKPCQbunI7q3Jp6 h8seOjf/ubmszQ4R62Ahwc3ITqyOyo822Z0wqFJdwOBELHq9XnCMj73QcS xmu2d78G5XO4gpFhrNp8tqIVx8x3PeQ1DITKg7Jal S3Vubq3DEfroPNWSuEIGQsQlQM0wky2oV FChGVLNzAiXjfcgBwkRnqJfsO9mz1THH2k/YV87zEeHQXDzj9YnQuXKDuqagJ1oA9NIdXnlm3Zkltb8c3Hdqn iD8U32myNoFmz8Qh8KhsUx1R2TIWm6CXhwk3lWKdLZGKbPYyLr XVDOYhF2dxiWxkry/bCunoOxvcRa7gld/WWnNXv17DM1 Z6DsTEt9qBF/ZGD9Zts6gvKoP2t7V2EoUCt4jEFiRAkJyQZsCwYvPGdiAwqT56 Dz7mOL7ZcZA5tt3n5KYOH5B4i Mss6FYFnYWxT8RFLLTxkLmOVHAz iRVT8WOflg0P74zzs4LiAYXm8nVBi9QAtCD0FgljJy8YZOyGo otNBC9zVZXULFnxW7BUU2USnQDCVN31 etcLH/D8vvnz/3ZuMSR2B1scAyhmUq0fg9cKg4pi/uV3nLcrkB0BRS8xRq SqirzL4iFe72okOiRg98 8LXilk eDIViUUm CjqfbfP7OW1F0THNzDshX3uita3CZnPYj6l2eGeu GCwwtCWuH/t5BSfYLSCLWRvr5cjxpCEC3/k2UooZ5V ReLb LnLdm/Zk8eW2TsDqQaAiHvey/3Nk6rng3a3FL4TPbf4j8XlDpuN2RcaUtk5Mzs5zlHyYtEZearG QVtgVgVD93YTJ/2Oh QkugQ0hCTwzWcOHl9dUZPrcLzfSJhMYHAhT9Rsev/v573wfGnTiZC5bf9xusJuYx2u/OeCDvpmziOS07k7ZC/fPuUOolYQpCAVveQdsUP2CMA00p0Idr7N8URcVVVd1eaN7xT4v J29vb2QCX1xT255t8G 9QDT0Mq7tsa2lC5z2FnbUSY Otg EztpklNjtn9QLAZAkKR6gVMuEN7xQVHptnPszrko1NA2xJXu3G Cvr6qrW73giV9CvdfbeaYXWn1m/T X7d/NMjZHu8DaGPHFICgzxLZ9G5fFzKK gDxiD2luaRUJhIAtfscpQoqVjtQh2EU7wywgCUs4EPyC6ptP/qa 5pPVG0M4n0JmkJY9jy4of wb6ytskP3ZtzfJLwWxbO27xzdv3MvPAgVcoH1ukdcTQIEdGSDg uE6iHphPOoS8ebGMXSSFH9cUfCju2yXzV/ m r3Ny0ix58WYrq9Zv6 d2Ri8Dwsxp80mtBY6HLay9ze/t6fZO4tsxknuufEej4dER4AWMnpE8Qk2Gid27Ghp8ZD6qr65JP 7x OUhm4AXVTZJycK9XG11XU2FXJ 74Yhqu8CWQ7Ul2lnWtrkmp6yGkb0zx4gguFXLm1oRhW8aCgwOg kSUt 5vOBD3UjOLKcRR63lcpXrs7bqa6uoqpyyyJLLqq6uq6utqcsvq l6qOOyvWO1mmBVA4cqpzq6o313pn1gso3aLjO5rbgYhoW4DRSz jBKcWGT3QsiItvaT3AO7GUEBmmpKQ07ugn9fWf1LE e4gdA8lZV1VdXlFxwJ777me19ceOCWzBi3ug/szJ3ZxblVvt886iWxY2HG5p5qWAfk rO0WQU59cHvqtF XmHQcKce6iyX606Uhb67Hjx22 mtpfFz9XjMWI5Kwq27jJZisrq6l2QGqvF3cHObAh8IU kQtmmhkFJ7grD fvbeSmiIEovGgLcBFy9cRjQYds26PXL8NI3X/6bJHqQOPhkmKmxf3Orw GCCTl1Vdt2bI55/33wUTQtTgcZ344XwIUsqx64uPc3BrfLGotyaZa8kIjqrYcKMK9 nDcgHcAQYe8LpetVuw6oXCBaO1rP8iFz44N25x39oGmpbdvXin tB4QBEVXXVx6uXQnpncQ5ObMhz2FzYupZtqapxPtwWBsUjjarg eY23 xHiEe/UC1StUn5B8JKmDTbwCH/6Al8xN1h1oKK28dCxj6vnxkhcfb2ztmpzWd3HT3zPx5HmXXBsr mHspGOtf/ dXOcM7PzRjwGFW3g OOQEFjXdXiISnQGbkNQqeMQi29KQJScZCBLOfvbzg5s/eYdp2aHyNjWUfXzi87MOzumrr6r6uO43bzOork634CrLab5gr2 FZ6FnfXZ1bP4sYARSHomNOytiU9qIiE2dwihBgT I64qh7 /nDArhZWF9yurU6t27L3vz4/d9reSGk6Ifbqmrqa6uqPqmqqatygCmcblYqmCvN 6GQUy84ne6a96tn7lNFZH7880XNXC/EJoQq6AWhqQIDAsXDHyn/9cboJQXYhm04cuECk7Nlc9mB5ue/VZD/3I64vdVltVWf1NXVVdfVYcEjcG63LXbT hL eC0Qo/DJLTN6hKiW5Ip/fr/AgVoAAqD8xQ5R6dGgP5J7XWd3766tWb8kZCtOpBTyRctLmPnb7 Y893nDsyPKYij1FR49WVe85Ciiq6liZTM8KwvF3qqGdY ySb9nfbvnY2TsLWwifPb 89GQvlP5ITbn3jEjYiSEIyV3smBf32WdFIbvtUOu7bUdUIaVtM fsr3tkbtPqz5Us2HNn9zup564MXfFxVDTiU4k8Sjr /GbqR9esl7uDcLbUz11oe CVb/I5dAnrBR6KD9OykesGOROw4tGvXvIKQfB6naRzbgw7Hv5TvaS2 rXzB/QXNDyZFTMRWbnsx57 NqcEtuvdIqCjWfVNfapWXz6 vZo 9zs5hpBPRs/qFdZGDMIZCosSvwdiq60Xui6UJLyWOhyw7zDCv5KmKC4k9Fzzv S2lr mwWPHnWU8W0t81e/V4X qKuuVeYyOLbmk3qhsXHuk7msUL1l5hocUcAlnmoN1Fl3UChVj9 xbuL DFw4FbTpSsLdRlpi8 aq4U0FBITsqbZvfq343913mTFxQCVx8Xd2va5wQItCtcq7cLbV 8R8PqnGpWLHt/xvkLks04p NYCQ4JLOiEGq7lZDfWWJ29KOq9Baojqvhdb7/H79qAznvPlRd8 tT6olLVL5nc31TXfVzjaomPL/8FRqrDySnTT25bbo2t0p7z9jGQjlwYYRbsdLKeQl6p9yCdenub m6aiFPow78GYvfvj336naEcJnOrbE9vLFjW0HooviYvd/egTObm5W2K3Nx9/t6amqqpMZN1uN0iE4CxeWsHH8szSQsFlK3PMphOAVrtTEgMtOz qkuZVMaHGkxOA6mlqbmBhVa1wltHGSLeigxDM7gkJ3Hik 9uK3tzqqc0KCtzcee7t88 Z3oHN1uzm3UxCKloRsb2ggM2Z2TGqzyGYuVm58QVBqCwTTfNJ3 ez6JEy8caA2KUR0C5jiAeL7QUB8v7wgJCTnTyZz6PL6YrcnfUM hUbLKV1eRu4t1uUHD4zzLbNzQyTie07AjFPmP1i0V48 EYpexECZc7PD6l IUuketotbNx /NL8htEBy5MFBRJgrwtZB/jEj2q0JYjbWddrhfWH7VV1NQcXxZ/TBags3C6na6aGrvEOl1uNwtc4We2BSf4tobmKbJN7s4o8SGTDr GjozLWU3JYFdzcIQL1nGRNicljIXsXqZZu2HG4NL5w73tHHY4y x6bnQrbXuNAWUFpU1zngweVmIb7FWVQ5wLllcbx3qicCWwRqPW zaOc/ZFx8vVZUEv9gh4qqAEycbSWMqtO76hoqfd pU0AbpeFlNbS27aVlpZ61EpkNdbE1VLet2QrHR JkwKxQCd6AF2NklK9UVyIUy5YiVFtfSevil0yUvqipbOJZEISs zx8jUSVHpjlD SOvnwRuPM7VQ5jnetbk3H2NYJ4YJC8UwThywLN8uzDi79mOcy3 G2tuE8OBm7k6ySQH5Vuk uucOT/0HRc3uYVg70SBDqBYkJKgR9dNpaO90VlZXLDjFlb f oqamuuwX7x85zdtZ8ISzJrfa4cZnx/bYoMOdhWpJ3P7SAAqSzkSxFxMseSUcaS3epwrJYzbYAa3TWV/b0SmFHvRJnBuFwLaHtdttHz 5ccu7ObbjZcJL32ZcLISI05Gby2KwOIs3QMv48G7ZQPRC4HbsF 5Was1eZXyO1BjrEJ8Qc3rdph0q1twBoAcaoq5e9QizHODio6hy kiRcktuJYxXHG/q7NFhd0nMWxnWx1tcDi5LYg4gT6jHN8OE144AjOXgSmvztFzuf zBtjq274rr6F0e gxD5F61rEHB5VUeyEHlgVmWwW5vux4WVnZnvXVcXF21kkWBWpq wH9uXE58oVG2zWLFSrZ92IIopiZdO5UXPuyT5MbS JKzB3Z0nHHiLC9Xu1HAxj240McJHmnqcP5i06Yad1xQ7ZNfm29 jcW2itqbaSRZZ3RUhe4X1s5gHl5ilvHfakgBJIT7iIQjV06rnC narLsigEBK/razOeYyRuK0slFQd3BQKrr6M2REXo3L orCh3AkGEGp/AShAOznWuWdf47LZoLBF88rMWqd8uzO73Qo0t 6qzD9wwQWXJlXMXVZWO3 ZRNYUWdFJpueBBZCLauO sd1Rl2vvaGRBMwVkJ7IUWOL zLV0JhQS1HGOmFO3UZApYFHuwpUKH3C0i9t/uuXChQsoFk5H4dwKZ9kmu yEnMV6YHiyKQDu5fp98wvd9bVlDFmzYGtyN6NuQMC4XC6hcOZZ FCjjOk5zgal4xCEqTaIi6ZxYcPhUa8cFnH13QidQX/dJjgNDg2M7ZKfiDzCIVP9uoU0oO1pLVu/cbPUnCi/cHK6zzjivheuDjjMdQmApkKxLEK90EmpwMtdS0tog/q4cL9kp eLeya2DZgxXQxjxzpqExOVsynEytnpWwlpLsOWUI0bMsBiwMys 4xzk8Z7EFmMIh3z6g8Oy1Xzhd2sZ38GThznnwW7F1dVV19U7g7 7JCWSkzyU6JmupcJ9nugEHkchW3KXM/Sss48ww0WbJSxiYmCKxNYkaB1N4bu0vYeEAQPOS6ucplez6uqp cQrz1oj4/sTpAICkfuZkFZb4R7tyuH4V0CWYedGQVNeCFwIunJOgO9MoHRS RZquN5lz89dXeCxkz0YnFy 5RPQI1y09Bbu8CCXJGX V6531JN8qgxbXl7eSF4gpFnwAosGztOpFDleEZ6ISowGTJL3XH BeUwfrwU93CvWb62o ricrl5JPkKctLDtrOKLnKOCgF V24hF8CUE i/URyWn3TFU4XrLzwHuHGjJzqKChw9PWZiNbH5zRcc4yn08O7ExR pnwUa7DYU0i48M BXuSwUyhm4xFEIVQ2K426d9qOFOXgOPGPRSWfxzOfHyPFhXTw8 aKgD1GulJVDxCCS5QRJ7MBByS4iCIwcVoHAuWfDTjKVyHkCMzc iqYDJpCdHii2OO3OB fylaM8fzjgkF9hajnssZI9sV5YDcE8V9Acy7jiQBTsuPBMmAIx mvIP BLOK0zVz3Yl2k6dKTYKCJFdOYQbXeXr588sPlXhkhnUwnwmu3f M21NULItnINLXwSjZjSA7SsJM1G4f9NOg3VDmcG7TTNUNmV6pf QUB/KDPhOLLIyVMT4WDsw0uWLFcVC4VFIrOHFezxXh6XZCTFdeReIB P1EjJBUKYwyjbz0CLhmjxU4S73zLaAC3DyntuNKbEFRxaWcQwf 135k9 7QApYpZkngFe7HH C qcC2BLJlivvBD/7xB9/9wXe/853vfv9734n897UD3/ XH3z3H//9//zgO98N 973fzBzHoGEKHQoIDhlnrFZyaqKNdrb2pqYX69fJpAdY4KwV2l FYWjBGzAHJ598dtHiZ55d/NQjc54J64vsH0iISAgLjwoLDw/rDw9fvGjRbPIIa2 Rp0dH87RNB7LQ0tTCOIqLcIMd9MHMMknZPSYENtGgbsonFz8T/uzCpxfOeXpxRP9AREJf MBARMRAX8Rv /ueWfzsd2ahWk62sRlzaGAPhnwyTlB2r8lods7T0lHv6C1y4KSr 89dH1xPNRu1AWnIkrUsnFy9eu3jOwoWLFkeBJfoiEsIj sL7 n4bGfHbvoSIp56dMY9gK4WbQAK5DLxyci6POYlcKCcLIm Tyy UOpAL9bk5m5CJZMuF8kh2IZwMWxwW/vQjTy2OHDgfHtUX0be2L/x8X99AX3/k YG f5jRFkoeafISqSCE6z34bY Ai N4gxzGF/Ds8QsdaAu5Iuft9 pYXE4UpnIp2e9nf aZRYue/punw8MG1kZF9vVFRPWFRUX0DQxE9cMt6uG2eJmsFUncyTivsmO MrEh8WHLWHhALvLfH7hLL/9hC9GNfjp2tr99bCABE0IwAfyTpZHj4MwsfeWrRM5HhYXD9EX0 R/f1rIwf6I/rPD4BNImbRCYDEHUQUU0i4lm F jD8BLLl0x79aJz8r4U4GrOnDreALphfhzDuMNh3Miz8qaefXdw XGRben5AQNgBB0oex0j8APOkPf2ZmdqLSiJ3YkgU0gmv7HtlWw SlyJOz95g/l4r12 Eneesyj8tb/kVOH64lIX2SF5Du56OlFkeEJAwMQHP2RMHB/RN95cMX3B/rW9vf3zRip7chOYFhnQDFwFM8ZqR1IgajgioWm0CZWzmcAE1td D6T07fz6/DJbB 73Q4Ohfn/4yFORkRAUaID tRH94X0RYZHhUeCXqIGB8zPwQkHBuoTbCoTrcaLYgjsqyWZXSF jCgd1n7R4PWU2trQFC9u589NQfoFIVlf1qQG7fh4vCkRBhCCQq Iaq/r6 /LwLNEhEBHHn2qVnslCIoZGXTL qEyDeTIonsAcZO7PCFBkYsZryS0NjEc3Lnwa9d AMYSvQEoluUPgSlDF/bD6HZh8MCgvDIhPDIviiI1qiEiNu2CGxsf/nlux7pV7H5xP2YpFDAekWU5MoSnClBuUa5FBqahEpe4DdA HI8w4HK7mjtINOkIkntcNrJRZHP9qH510YNhPf1h68F9/RHRPadD084vzYy8jY7X37Q48ukTyUoBGIJ3GMDeEqxV0NNBG6A pPHRTS1N8kEG9xPW4h4zT tO3MPICbifBplxciHEx/l CImEvrC14A8wB8QrYAGjRESGz6EfchAUrJ3DqThSLZBSlrPH8F 5gPu6elblGoblFtb25xdPAoFiVzz99RjgTt0AO1HOEF8DO8Ij vvMJA2vDEyLDzoNuQaRERvVDgPTD0/A5GRnpGenp6RmBx/Q7jxkZBupVF tgOVbetrOXMIMQ8mQ j3jAN3C9Lr7Z80HwCy VeEgWYx7dfbaFf3uvSw5UlRCqrPThI88khIef7 8Lj4gaADxw X1gi74ECJkweHeO4SEHxIibdTgqOTk2tlcgHQcML/BNuK6pFFCQcsWOOJUq6HAlaXnYOFXT8Y37DoQwxBm4j1Jg3R/ 3VN9kL4GBjA6IVCiIsMhsUYCUTCZ9D2LHsG/1PMy SIPRdF68pd76JfxPWVXOjPfLm NxcyO2 LhEht4bFFk A/sA1N0NLVsVy2PZ8nkXcfzB5mmZs9jcd6pfgN48eGcsLBFEQlRE eERaAEIlIiECDz6w6NASIhq0foUE5WsM5oMpiTjqmQTZUwyUkb TT1bRNKIoDmJ820LJLmaJsIHn2wWl64IXEJxFTU0d 5cvz4fuW6g/E1/MezzFj21DKVF6IE74cM6chZH/ANVNP2hFZBhAwaiN6E8I64sK7w9/Gr/pZRo0da9bN5iRZhxOSe1Ozsy0dA azZfNQ2sIisq5gGJ QC1w4K2xsrLxH7cR8w0HQvfPa2g6tFx1wiW4HfIFQW5saJi3VR bkqXYDeDEnfC1Q4vxAOMhEZBhwErR8LSjY ai1UX2oWuqe7sSkkcTLbyXqr5gtlxINw28Mdpl MrSyq/uffowxUsh5t4WIRH5wZFGlUoiHVZ1Qua8odPfXD4qtu0NacVKX 7RTdsYfBYHgGT6a9IUb Zs6isGdAMIANimpFne9fDDIOXIHnYYBCa72UmDpMWUZM9LAp7Y rGdHnd0CVT8tA/XXxD/WMe56kF eBc5KKIigktxzKhXWm4BLunaO8R1ZFfNpScKglpEl1kB6mg2g9 3Ho8AXYeI iZ/OOcRqPWeWtuPig0k/QfIpxAj4JSIyKhAfaHLSrMmWVMzzpkvG7WZGetSzD9P nnGxVQLDey0u8hVFYvtuH2Y5PP9sfaGE5DNoBjPa45bz6v45kO lpYfzj/CIAt5uOpx3gsdDCMjdyTmPPLIIVTshIQqEOxIitg/iY6C/PwHSStRiop0aIwQHpaX0 PfbDLSWXkVp4F6jR14oO8pBviEpCMg4sZln1kMmh FsG5qW5Qk7xeLS0tL4XS3N0OC4BK nc15QsehpEm/z4uQcMMazYaCcff0JiwEG4Ej4LaSS/r61kRFhi8h3 9OTLK lZaSCXqWmpaVlJBstlrT0tNcy9KhagaVxyAknCO0FsamgMo8Xx XZRZPKaChoBYdOR0kPPlza3t2Pi6zxzInhuc0dzsyAGdEv6cCE YY84zGKKQwfoj1g5EhoFHohL6 8L6w6LC55A/tJOUkZ6alrIuw5puMZtTk41pljcs6ZZ1ECONdpbEGsd37lwKbA SFEItiTxzgyQhMXgOP8xDFy3ccjj/lEQkKwSNEh7aLfKPIFJMkCLxYOOdvHpnzdHjEWuhDwoELmODDI wbAQ5ERa9cqvMA/KaXHP4OiU77bT76YiN/2BxTINx4/3BMb7cJvnAhyUbTicRCLohLeDj9sWL78cOupVkFU5uzkrfPxN8 TGRrIlW w8OWch GThswAhMgryWFhkZEJkArQmUO6BX6ICf52F1it/WYBWQN3 K0VrGgOu5XlxGXYAeGWVsfz2YuCJx9PY0Gq3u6DQbYqPLylpIm diOcLjV2TwIBkPUcx5ZM7fQbRCrYMlxuIIqDCiQDYToC3AbIbD mvALsrTpFRBR8idWdIakVYFaqylw1UKjJzSokhBDlPnW57byYm dx7InmJgLTJRzOL1m m3iJRSYTLO1oCXyPO7lw4SNgjqcAR RayGGQykDMIWahzIB8QmpwOu0Na4r1jTesVmu2dZ0Vj2xzmtWa odOvaRJ51o4ZiffGhdhFtIXACK3LQ0LbG6KjC4pVDNrexR/5oHT5LhzRLp7xioKdFGgCqYzgdnLONx95ZOHTixY /SzkMpAIuEFqfwmSPdQdii30qakpyT81p6SkJKe/lpyakmROwxdpVppe08SSQxAONvDFIqmvmOjiXSFLgkPy50bn5w flEUvFBec3NzSJUFiBYHg6AvZDj C3NrwnHyH0XPj0nEXfh QOzhjoDwOLgJRDK5Cg9CM68pVA1AwanuIN7lfpDXrqp60MVDkc z4ohMZ6p2IveHvdoaL4q/rHogg Ct2MOE KCdvKNbR7uJNnETkiMN/w6kggVPHgEQxU61aefioiKHFgLDIWsCrmtH9SrP3x69atEyJ3X NPCiwebABU eV 1sBYYSY zbvku1o6Vl TdimltC5jciA14MbmipbG1TJlHtBABDcJCvYnkhm82Z89RTT6M xoNwBzRqA6gLUYqC/D3nxfwEx8jDbC7crnAAAAABJRU5ErkJggg==[/IMG]

  6. #6
    Join Date
    Jun 2012
    Location
    America
    Posts
    22,125

    Just to give an a tiny idea!

    • We know much !





    • 7. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661.
      Abstract/FREE Full Text
    • 8. Chan, S. Y., C. J. Empig, F. J. Welte, R. F. Speck, A. Schmaljohn, J. F. Kreisberg, and M. A. Goldsmith. 2001. Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106:117-126.
      CrossRefMedline
    • 9. Colebunders, R., and M. Borchert. 2000. Ebola haemorrhagic fever—a review. J. Infect. 40:16-20.
      CrossRefMedline
    • 10. Connolly, B. M., K. E. Steele, K. J. Davis, T. W. Geisbert, W. M. Kell, N. K. Jaax, and P. B. Jahrling. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179:S203-S217.
      Abstract/FREE Full Text
    • 11. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617-648.
      CrossRefMedline
    • 12. Feldmann, H., H. Bugany, F. Mahner, H. D. Klenk, D. Drenckhahn, and H. J. Schnittler. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70:2208-2214.
      Abstract/FREE Full Text
    • 13. Feldmann, H., S. T. Nichol, H. D. Klenk, C. J. Peters, and A. Sanchez. 1994. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199:469-473.
      CrossRefMedline
    • 14. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8:503-507.
      CrossRefMedline
    • 15. Gupta, M., S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin. 2001. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75:4649-4654.
      Abstract/FREE Full Text
    • 16. Ito, H., S. Watanabe, A. Sanchez, M. A. Whitt, and Y. Kawaoka. 1999. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 73:8907-8912.
      Abstract/FREE Full Text
    • 17. Ito, H., S. Watanabe, A. Takada, and Y. Kawaoka. 2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75:1576-1580.
      Abstract/FREE Full Text
    • 18. Jahrling, P. B., J. Geisbert, J. R. Swearengen, G. P. Jaax, T. Lewis, J. W. Huggins, J. J. Schmidt, J. W. LeDuc, and C. J. Peters. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. 11(Suppl.):135-140.
    • 19. Jahrling, P. B., T. W. Geisbert, D. W. Dalgard, E. D. Johnson, T. G. Ksiazek, W. C. Hall, and C. J. Peters. 1990. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335:502-505.
      CrossRefMedline
    • 20. Johnson, K. M., J. V. Lange, P. A. Webb, and F. A. Murphy. 1977. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet i:569-571.
    • 21. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
      CrossRefMedline
    • 22. Kindzelskii, A. L., Z. Yang, G. J. Nabel, R. F. Todd III, and H. R. Petty. 2000. Ebola virus secretory glycoprotein (sGP) diminishes FcγRIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164:953-958.
      Abstract/FREE Full Text
    • 23. Malashkevich, V. N., B. J. Schneider, M. L. McNally, M. A. Milhollen, J. X. Pang, and P. S. Kim. 1999. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution. Proc. Natl. Acad. Sci. USA 96:2662-2667.
      Abstract/FREE Full Text
    • 24. Maruyama, T., L. L. Rodriguez, P. B. Jahrling, A. Sanchez, A. S. Khan, S. T. Nichol, C. J. Peters, P. W. Parren, and D. R. Burton. 1999. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73:6024-6030.
      Abstract/FREE Full Text
    • 25. Parren, P. W., T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton. 2002. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76:6408-6412.
      Abstract/FREE Full Text
    • 26. Peters, C. J., and A. S. Khan. 1999. Filovirus diseases. Curr. Top. Microbiol. Immunol. 235:85-95.
      Medline
    • 27. Ploegh, H. L. 1998. Viral strategies of immune evasion. Science 280:248-253.
      Abstract/FREE Full Text
    • 28. Sanchez, A., A. S. Khan, S. R. Zaki, G. J. Nabel, T. G. Ksiazek, and C. J. Peters. 2001. Filoviridae: Marburg and Ebola viruses, p. 1279-1304. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott, Williams & Wilkins, Philadelphia, Pa.
    • 29. Sanchez, A., S. G. Trappier, B. W. J. Mahy, C. J. Peters, and S. T. Nichol. 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93:3602-3607.
      Abstract/FREE Full Text
    • 30. Sanchez, A., Z. Yang, L. Xu, G. J. Nabel, T. Crews, and C. J. Peters. 1998. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72:6442-6447.
      Abstract/FREE Full Text
    • 31. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
      CrossRefMedline
    • 32. Simmons, G., J. D. Reeves, C. C. Grogan, L. H. Vandenberghe, F. Baribaud, J. C. Whitbeck, E. Burke, M. J. Buchmeier, E. J. Soilleux, J. L. Riley, R. W. Doms, P. Bates, and S. Pohlmann. 2003. DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115-123.
      CrossRefMedline
    • 33. Simmons, G., R. J. Wool-Lewis, F. Baribaud, R. C. Netter, and P. Bates. 2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76:2518-2528.
      Abstract/FREE Full Text
    • 34. Ströher, U., E. West, H. Bugany, H.-D. Klenk, H.-J. Schnittler, and H. Feldmann. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75:11025-11033.
      Abstract/FREE Full Text
    • 35. Sui, J., and W. A. Marasco. 2002. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 303:9-14.
      CrossRefMedline
    • 36. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z.-Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
      CrossRefMedline
    • 36a. Sullivan, N. J., T. W. Geisbert, L. Xu, Z.-Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for ebola virus hemorrhagic fever in non-human primates. Nature 424:681-684.
      CrossRefMedline
    • 37. Takada, A., S. Watanabe, H. Ito, K. Okazaki, H. Kida, and Y. Kawaoka. 2000. Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20-26.
      CrossRefMedline
    • 38. Tighe, H., M. Corr, M. Roman, and E. Raz. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19:89-97.
      CrossRefMedline
    • 39. Vanderzanden, L., M. Bray, D. Fuller, T. Roberts, D. Custer, and K. Spik. 1998. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246:134-144.
      CrossRefMedline
    • 40. Villinger, F., P. E. Rollin, S. S. Brar, N. F. Chikkala, J. Winter, J. Sundstrom, S. R. Zaki, R. Swanepoel, A. Ansari, and C. J. Peters. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179:S188-S191.
      Abstract/FREE Full Text
    • 41. Volchkov, V. E., S. Becker, V. A. Volchkova, V. A. Ternovoj, A. N. Kotov, S. V. Netesov, and H. D. Klenk. 1995. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214:421-430.
      CrossRefMedline
    • 42. Volchkov, V. E., V. A. Volchkova, E. Muhlberger, L. V. Kolesnikova, M. Weik, O. Dolnik, and H.-D. Klenk. 2001. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291:1965-1969.
      Abstract/FREE Full Text
    • 43. Watanabe, S., A. Takada, T. Watanabe, H. Ito, H. Kida, and Y. Kawaoka. 2000. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74:10194-10201.
      Abstract/FREE Full Text
    • 44. Weissenhorn, W., A. Carfi, K. H. Lee, J. J. Skehel, and D. C. Wiley. 1998. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2:605-616.
      CrossRefMedline
    • 45. Wilson, J. A., M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666.
      Abstract/FREE Full Text
    • 46. Wyers, M., P. Formenty, Y. Cherel, L. Guigand, B. Fernandez, C. Boesch, and B. Le Guenno. 1999. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. J. Infect. Dis. 179:S54-S59.
      Abstract/FREE Full Text
    • 47. Xu, L., A. Sanchez, Z. Yang, S. R. Zaki, E. G. Nabel, S. T. Nichol, and G. J. Nabel. 1998. Immunization for Ebola virus infection. Nat. Med. 4:37-42.
      CrossRefMedline
    • 48. Yang, Z.-Y., H. J. Duckers, N. J. Sullivan, A. Sanchez, E. G. Nabel, and G. J. Nabel. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886-889.
      CrossRefMedline
    • 49. Yang, Z.-Y., R. Delgado, L. Xu, R. F. Todd, E. G. Nabel, A. Sanchez, and G. J. Nabel. 1998. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279:1034-1037.
      Abstract/FREE Full Text
    • 50. Zaki, S. R., W. Shieh, P. W. Greer, C. S. Goldsmith, T. Ferebee, J. Katshitshi, F. Tshioko, M. Bwaka, R. Swanepoel, P. Calain, A. S. Khan, E. Lloyd, P. Rollin, T. G. Ksiazek, and C. J. Peters. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of E






    http://jvi.asm.org/content/77/18/9733.full

  7. #7
    Join Date
    Oct 2014
    Posts
    238
    And then there was the speaker at the Ebola conference who said that he knew less now about Ebola than he did six months ago. He claimed to have read 700 of this type of study, too.

  8. #8
    Join Date
    Jun 2011
    Location
    life elevated
    Posts
    1,343
    [quote name="Inthedetails" post=11150182]When someone has active ebola, from what I understand, they are dreadfully sick. I don't think it would be difficult to "round them up." You would't have to chase them on a bicycle ride, for example.[/QUOTE] annahanna
    Dr Spencer ran 3 miles, went bowling, and dined in a restaurant after traveling on several subway lines the day before he was hospitalized and tested positive for Ebola.

    Jumping off this post from the last thread about Dr Spencer's movement around town.
    I was not aware he lied when first asked where he had been. If true why did he feel he needed to lie?

    http://www.foxnews.com/health/2014/1...ments-in-city/

    CDC posting info then pulling it back IMO causes confusion and mistrust. Once a protocol is established about quarantine hopefully all the states can get on the same page. Jmo

    http://nypost.com/2014/10/30/cdc-pul...ough-a-sneeze/

    ciao

  9. #9
    Join Date
    Jan 2014
    Posts
    1,268
    Cariis, you have many great posts, but I have to say you are a terrible typist. And since I'm not too good myself, that's saying a lot.

  10. #10
    Join Date
    Jun 2012
    Location
    where the big sharks come to play
    Posts
    5,569
    And for those that think this is all about spreading fear, I have two questions:
    What is the magic number that fear is "acceptable" by them to commence--is it somewhere between the 50 million deaths due to the Black Plague or the 4 deaths in the USA from Ebola? What's their magic number?

    And second, who holds the honor of telling anyone when to be afraid?
    - - - - - - - - - - - - - - - -
    "Look, if any of us wanted to mind our own business, we wouldn't be here" (carbuff 8/11/13)

    This post reflects my constitutionally-protected opinion. Please do not copy it anywhere else outside of the WebSleuth forum


  11. #11
    Join Date
    Mar 2013
    Location
    TX
    Posts
    349
    Jumping off this post from the last thread about Dr Spencer's movement around town.
    I was not aware he lied when first asked where he had been. If true why did he feel he needed to lie?

    http://www.foxnews.com/health/2014/1...ments-in-city/


    My reply:

    I'll wait until all the facts come out before believing the doctor lied. It just doesn't jive with the profile of who he seems to be from what I've read.

    When the Ebola scare began here in Dallas, there was SO much misinformation printed only to be corrected as more facts came out.

  12. #12
    Join Date
    Jun 2012
    Location
    America
    Posts
    22,125

    Vital distinction! Huge

    The media keeps mixing up animal virus, which do mutate, and can change transmission modes. For us no! Thank god!

    For the virus to be transmissible through the air like the common cold, it would have to mutate.

    “We know the virus hasn’t changed,” Adalja said. No virus that infects humans (huge distinction IMO - media carries on about mutating). has ever been known to mutate and change the way it spreads.

    So vital again: No virus that infects humans has ever been known to mutate and change the way it spreads.

    The two viruses are different in that HIV has a long latency period. Someone can be infected and not show symptoms for as long as 10 years; all the while they are able to transmit the disease. There is a much shorter latency period for Ebola — typically shorter than 21 days. Symptoms appear quickly, and a person needs to be actively exhibiting symptoms in order to spread the virus, Adalja said.

    The implication here is huge as well IMO. For 10 years, without knowing , folks can give it to others. Certainly that has impacted its numbers globally.

    http://www.healthline.com/health-new...-aids-101414#4

  13. #13
    Join Date
    Jan 2014
    Posts
    1,268
    Quote Originally Posted by ATasteOfHoney View Post
    And for those that think this is all about spreading fear, I have two questions:
    What is the magic number that fear is "acceptable" by them to commence--is it somewhere between the 50 million deaths due to the Black Plague or the 4 deaths in the USA from Ebola? What's their magic number?

    And second, who holds the honor of telling anyone when to be afraid?
    Anyone is entitled to be afraid all they want. But they should not be able to use fear to dictate public health policy just because they are afraid.

  14. #14
    Join Date
    Oct 2014
    Posts
    238
    Quote Originally Posted by ATasteOfHoney View Post
    And for those that think this is all about spreading fear, I have two questions:
    What is the magic number that fear is "acceptable" by them to commence--is it somewhere between the 50 million deaths due to the Black Plague or the 4 deaths in the USA from Ebola? What's their magic number?

    And second, who holds the honor of telling anyone when to be afraid?
    Actually, back in August I brainstormed the degree of personal concern I'd feel at each stage of this outbreak. (As opposed to a more general concern for the suffering of Africa.)

    I felt cheerfully unconcerned about any danger from the people they were bringing back for treatment.

    First stage of concern was going to be when someone came back from Africa, not knowing that they had been infected with it, and had to be diagnosed from scratch. That was Duncan.

    Second stage of concern was going to be when someone who hadn't left this country caught it here. That was Nina Pham.

    Third stage of concern: if it showed any signs of spreading beyond the initial realization that there's a problem. That was Nina Pham and Amber Vinson--by golly, I wasn't expecting us to let medical personnel catch it from a patient known to have it! But, it starts to look as though we've got our act back together. And also, the fact that Duncan's hosts didn't catch it was immensely reassuring, and surprising. So, I've cooled back to second stage of concern.

    Fourth stage of concern: if anyone in this country gets it and they can't figure out the source of the infection.

    Fifth stage of concern: if so many people catch it that figuring out the source of the infection is hopeless or pointless.

    Sixth stage of concern, aka red alert: if the fourth or fifth stage is happening in my county, or if someone I know is under quarantine.

    I expected the first and second stages to happen. I expected the third to happen, but maybe it won't, if we get serious about disease control. I really don't expect the fourth and fifth to happen.

    Anyone else want to comment on their feelings?

  15. #15
    Join Date
    Sep 2009
    Posts
    25,216
    That isn't accurate. There isn't something special about human viruses that makes them unable to mutate.
    Human viruses mutate all the time.
    Ebola virus is mutating very rapidly.

    "By comparing their data to the Guinean sequence data, Goba's team confirmed that Ebola was probably imported to Sierra Leone by 12 people who attended the funeral in Guinea, and that the West African outbreak originated in a single event in which the virus passed from an animal into a person. Further comparisons suggest that the virus that caused the outbreak separated from those that caused past Ebola outbreaks about 10 years ago. It had accumulated more than 395 mutations between that time and June, when the researchers collected the last samples included in today's analysis."

    http://www.nature.com/news/ebola-vir...preads-1.15777
    Just my opinion

Page 1 of 57 1 2 3 11 51 ... LastLast


Similar Threads

  1. Ebola outbreak - general thread #8
    By Harmony 2 in forum Up to the Minute
    Replies: 1098
    Last Post: 10-30-2014, 09:47 PM
  2. Ebola outbreak - general thread #6
    By Harmony 2 in forum Up to the Minute
    Replies: 1127
    Last Post: 10-17-2014, 10:23 AM
  3. Ebola outbreak - general thread #5
    By Harmony 2 in forum Up to the Minute
    Replies: 1397
    Last Post: 10-15-2014, 07:26 PM
  4. Ebola outbreak - general thread #4
    By Harmony 2 in forum Up to the Minute
    Replies: 1112
    Last Post: 10-13-2014, 12:34 AM
  5. Ebola outbreak - general thread #3
    By Harmony 2 in forum Up to the Minute
    Replies: 988
    Last Post: 10-09-2014, 12:44 AM